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1  | INTRODUC TION
Patients with cardiac diseases or conditions with high risk of de-
veloping cardiac diseases undergo risk assessment by cardiolo-
gists, primary care physicians, and scientists based on referral for 
more advanced risk assessment strategies, institution of preven-
tive treatments, counselling of patients and their relatives, and se-
lection of patients for scientific trials. The various methods used 
for risk assessment differ with respect to availability, complexity, 
and usefulness in different patient populations. Parameters asso-
ciated with increased risk of e.g. death may also be associated with 
higher risk of other adverse outcomes. However, risk assessment 
strategies including specific methods for risk assessment and risk 
scores should be used only for the purposes for which they are 
validated.
This expert consensus statement of the European Heart 
Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia 
Pacific Heart Rhythm Society (APHRS), and the Latin American 
Heart Rhythm Society (LAHRS) summarizes the consensus of the 
international writing group based on a thorough review of the med-
ical literature regarding risk assessment in cardiac arrhythmias. To 
create a tool for clinicians to perform rational and evidence-based 
risk stratification, this task force was set down by EHRA, HRS, 
LAHRS, and APHRS, including representatives from each of the 
four societies.
With this document, we intend to describe and review status 
of performing risk assessment in different patient populations with 
cardiac diseases or conditions with high risk of developing such. 
Our objectives are to raise awareness of using the right risk assess-
ment tool for a given outcome in a given population, and to provide 
physicians with practical proposals that may lead to improvement 
of patient care in this regard. For quick reference, sub-chapters 
start with a short section on consensus statements. The document 
concludes with a summary of consensus statements.
1.1 | Evidence review
Members of the Task Force were asked to perform a detailed litera-
ture review using PubMed and EMBASE, weigh the strength of evi-
dence for or against a particular treatment or procedure, and include 
estimates of expected health outcomes for which data exist. Patient-
specific modifiers, comorbidities, and issues of patient preference 
that might influence the choice of particular tests are considered, as 
are frequency of follow-up and cost-effectiveness. In controversial 
areas, or with regard to issues without evidence other than usual 
clinical practice, consensus was achieved by agreement of the expert 
panel after thorough deliberations. This document was prepared by 
the Task Force and peer-reviewed by official external reviewers rep-
resenting EHRA, HRS, APHRS, and LAHRS.
Consensus statements are evidence-based and derived primar-
ily from published data or determined through consensus opinion 
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if no data available. Current systems of ranking level of evidence 
are becoming complicated in a way that might compromise their 
practical utility.1 In contrast to guidelines, we opted for an easier 
user-friendly system of ranking using ‘coloured hearts’ that should 
allow physicians to easily assess the current status of the evidence 
and consequent guidance (Table 1). This EHRA grading of consen-
sus statements does not have separate definitions of the level of 
evidence. The categorization used for consensus statements must 
not be considered directly similar to the one used for official society 
guideline recommendations which apply a classification (Class I-III) 
and level of evidence (A, B, and C) to recommendations used in of-
ficial guidelines.
Thus, a green heart indicates a ‘should do this’ consensus 
statement or indicated risk assessment strategy based on at 
least one randomized trial or supported by strong observational 
evidence that it is beneficial and effective. A yellow heart indi-
cates general agreement and/or scientific evidence favouring 
a ‘may do this’ statement or the usefulness/efficacy of a risk 
assessment strategy or procedure. A ‘yellow heart’ symbol may 
be supported by randomized trials based on a small number of 
patients or not widely applicable. Risk assessment strategies 
for which there is scientific evidence of no benefit or potential 
harm and should not be used (‘do not do this’) are indicated by 
a red heart.
Finally, this consensus document includes evidence and expert 
opinions from several countries. The risk assessment approaches 
discussed may therefore include tests not approved by governmen-
tal regulatory agencies in all countries.
1.2 | Relationships with industry and other conflicts
All members of the writing group, as well as reviewers, have dis-
closed any potential conflicts of interest. Details are available in 
Supporting Information online.
All consensus statements were voted upon by the writing com-
mittee independently and reached the predefined level of ≥75% 
consensus for inclusion in consensus statement tables. Each partner 
society officially reviewed the document, and all reviewer comments 
were addressed. Each partner society approved the final document 
and consensus statements.
2  | GENER AL TOOL S FOR RISK 
A SSESSMENT, STRENGTHS, LIMITATIONS, 
AND PRETEST PROBABILIT Y
2.1 | Value of clinical history and characteristics 
including clinical risk scores such as CHA2DS2-VASc
Clinical assessment of the patient with cardiac arrhythmias starts 
with a good clinical history and basic investigations for an un-
derlying aetiological factor for the arrhythmia or its associated 
complication(s). In addition, an assessment of the risks and benefits 
of any therapeutic intervention should be made, and appropriate 
management initiated.
Following on from clinical history and assessment, there is a pro-
posal toward a more integrated and holistic approach to arrhythmia 
management, as evident in guidelines. Such an integrated approach 
requires multidisciplinary teams of healthcare professionals, pa-
tient involvement, access to treatment options, and decision-sup-
port tools to optimize the patient journey. Many proposals have 
been made towards the operationalization of such an integrated 
approach to risk assessment and practical management in cardiac 
arrhythmias, which has been of varying complexity. As an example, 
the management of atrial fibrillation (AF) has been simplified into 
the ABC pathway (‘A’ Avoid stroke with Anticoagulation; ‘B’ Better 
symptom management, with patient-centred and symptom-directed 
decisions on rate or rhythm control; ‘C’ Cardiovascular and comor-
bidity risk management), which has been shown to be associated 
with improved clinical outcomes and reduced healthcare costs.2–6
This makes a strong argument for using the right approaches and 
clinical tools for patient assessment, but using them appropriately 
for the reasons they were first proposed (e.g. stroke risk scores to 
assess stroke risk, and not other outcomes).
Taking AF as an illustrative example with regard to using the right 
score for the right reason there are many risk factors for stroke 
(but the more common and validated ones have been used to for-
mulate risk stratification tools).7 The most common in use is the 
TA B L E  1   Scientific rationale of consensus statements
Definitions related to a 
treatment or procedure
Consensus statement 
instruction Symbol
Scientific evidence that a 
treatment or procedure is 
beneficial and effective. 
Requires at least one 
randomized trial, or is 
supported by strong 
observational evidence 
and authors’ consensus (as 
indicated by an asterisk).
‘Should do this’
General agreement and/or 
scientific evidence favour 
the usefulness/efficacy of 
a treatment or procedure. 
May be supported by 
randomized trials based on 
a small number of patients 
or not widely applicable.
‘May do this’
Scientific evidence or 
general agreement not 
to use or recommend a 
treatment or procedure.
‘Do not do this’
The categorization for our consensus document should not be 
considered directly similar to the one used for official society guideline 
recommendations which apply a classification (I-III) and level of 
evidence (A, B, and C) to recommendations.
     |  557NIELSEN Et aL.
CHA2DS2-VASc score
8 but it is not meant to include every possible 
stroke risk factor, and was designed to be simple, reductionist and 
practical to help decision-making for stroke risk. As with all clini-
cal scores based on clinical factors, the CHA2DS2-VASc score only 
performs modestly for predicting high-risk patients who sustain 
events. The use of more clinical factors and biomarkers improves 
prediction (at least statistically) but the practical added value is 
marginal, and less impressive in real-world cohorts.9,10 Use of sim-
plified scores to artificially categorize patients into low-, moder-
ate- and high-risk strata can be problematic, as in the real-world 
patients do not necessarily fall into three neat categories of risk. 
Also, not all risk factors carry equal weight, hence, the move to 
focus the initial decision-making on identifying low-risk patients 
who do not need antithrombotic therapy first, following which 
stroke prevention can be offered to AF patients with ≥1 stroke 
risk factors.9 Stroke risk is also highly dynamic, and although lo-
gistically challenging, a clinical reassessment may be needed every 
4-6 months to optimize risk re-assessment.11–13 As the CHA2DS2-
VASc is a cluster of common cardiovascular risk factors, it is pre-
dictive of death, cardiovascular hospitalizations, and other adverse 
outcomes that the CHA2DS2-VASc score was not designed for. 
Also, given that many components of the CHA2DS2-VASc score 
are associated with incident AF, the CHA2DS2-VASc score is used 
to predict new onset AF, again something it was not designed for. 
Another misuse of the CHA2DS2-VASc score is the prediction of 
bleeding risk. Nevertheless, formal comparisons show that the 
CHA2DS2-VASc (and older CHA2DS2) score are inferior to a formal 
bleeding risk score such as the HAS-BLED score, for the prediction 
of major bleeding in AF patients.14
Indeed, bleeding risk is also highly dynamic, and the appropriate 
use of bleeding risk scores such as HAS-BLED is to address modifi-
able bleeding risk factors (e.g. uncontrolled hypertension, labile INR, 
concomitant aspirin, or NSAID use) then to schedule the ‘high risk’ 
patients for early and more frequent follow-up visits (e.g. 4 weeks 
rather than 4 months).15 Only focusing on modifiable bleeding risk 
factors is an inferior strategy for bleeding risk assessment, compared 
to the HAS-BLED score.8
We should use the scores only for the purposes they were de-
signed for. Attention to appropriate methodology, statistics, etc.—
as well as other clinical states merits consideration e.g. sudden 
death prediction (or failed ablation, device infection, etc.), Charlson 
Comorbidity Index, frailty etc.—but using the right score designed 
for that purpose.
If appropriately used, some of these (simplified) tools help with 
clinical management. Indeed, the value of a medical test is measured 
by its accuracy as well as how it impacts medical decisions and ulti-
mately patient health. As medical tests are considered and new ones 
emerge, they should be considered and evaluated in a framework of 
accuracy and patient impact.16 A test must not only be accurate, but 
also feasible. Tests that are difficult to reproduce, subject to techni-
cal failures, or difficult to interpret are likely to impact patient care 
as a consequence of a primary failure to produce a definitive and 
actionable result.
2.2 | Electrocardiographic methods 
including monitoring
Electrocardiographic methods 
including monitoring Class References
Twelve-lead electrocardiogram (ECG) 
should be obtained in all patients 
undergoing evaluation for known or 
suspected heart disease.
17
The 12-lead ECG provides diagnostic 
and prognostic information in patients 
with inherited high-risk syndromes 
including long QT syndrome (LQTS), 
short QT syndrome, Brugada 
Syndrome, and arrhythmogenic 
cardiomyopathy and should be 
obtained.
17
Exercise ECG provides diagnostic 
and prognostic information for 
patients with LQTS arrhythmogenic 
cardiomyopathy, hypertrophic 
cardiomyopathy (HCM), 
catecholaminergic polymorphic 
ventricular tachycardia, and 
documented or suspected arrhythmias 
related to exertion, and should be 
obtained.
17
Ambulatory ECG evidence of non-
sustained ventricular tachycardia 
provides prognostic information 
in ischaemic cardiomyopathy, 
arrhythmogenic cardiomyopathy, and 
HCM and should be obtained.
17
The signal-averaged ECG and QRS 
fragmentation may aid in the diagnosis 
of arrhythmogenic cardiomyopathy.
18
The signal-averaged ECG and QRS 
fragmentation may be useful in risk 
stratification of Brugada syndrome.
18
Heart rate variability, heart rate 
turbulence, signal-averaged ECG, 
and T wave alternans analysis, when 
used in combination with additional 
clinical, electrocardiographic, and 
structural measures, may be useful 
for identifying high- and low-risk 
groups among patients with acquired 
structural heart disease.
19
2.2.1 | Electrocardiographic methods
The ECG is the gold standard for risk assessment in patients with or 
at risk of developing cardiac arrhythmias. The 12-lead ECG is inex-
pensive and widely available. Risk stratification with the ECG is lim-
ited in general by its low positive predictive value (PPV) determined 
to a large extent by the low prevalence of cardiovascular events in 
the general population. However, the prognostic significance of the 
ECG is enhanced in patients with heart disease.
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2.2.2 | P wave and PR interval
The prognostic value of P wave characteristics has been examined 
in subjects enrolled in clinical trials of AF for prediction of the de-
velopment of AF, where maximum P wave duration was a significant 
independent risk marker for the development of AF over 10 years.20 
This observation was confirmed by epidemiologic/population stud-
ies (including ARIC and the Copenhagen ECG studies) that showed 
increased risk of AF in patients with prolonged P wave duration 
and PR interval prolongation,21–23 and summarized in a review by 
Nikolaidou et al.24 Moreover, a prolonged P wave duration was de-
termined as a sensitive predictor of post-operative AF in patients 
undergoing coronary artery bypass grafting (CABG).25 The defini-
tion of an abnormal P wave varies greatly depending on how it is 
measured, and definitions vary depending on whether P wave area, 
duration, terminal forces in lead V1 or signal-averaged P wave are 
analysed. Abnormal P wave morphology was associated with in-
cident stroke in the Multi-Ethnic Study of Atherosclerosis.26 The 
prognostic significance of PR interval prolongation, which is vari-
ably defined as PR intervals greater than 196-220 milliseconds, is 
controversial and depends on the patient population studied. Most 
studies show that PR interval prolongation is not associated with in-
creased mortality in healthy middle-aged individuals during medium 
term follow-up. On the other hand, a number of reports show worse 
survival in patients with suspected heart failure (acute and chronic) 
or heart disease (coronary artery disease [CAD]). Additionally, PR 
prolongation and P wave prolongation predict increased risk of AF 
and the greater degrees of PR prolongation and P wave duration 
predicted higher risks of AF.27,28 An increased PR interval is also as-
sociated with poor cardiovascular outcomes in patients with AF.29 
Several studies have shown that PR prolongation in patients under-
going cardiac pacing or receiving cardiac resynchronization therapy 
(CRT) is an independent predictor of worse prognosis and lower 
probability of reverse remodelling as well as an increased risk of AF, 
death, and hospitalization.30,31 There are no data indicating whether 
the degree of PR prolongation portends a worse outcome compared 
to patients who have lesser degrees of PR prolongation, nor is there 
information on its prognostic value in acute inferior wall myocardial 
infarction (MI).
2.2.3 | QRS, QT interval, and T-wave
Over the years, a number of ECG techniques have been developed 
to assess risk of ventricular tachyarrhythmias (VTs). These have the 
advantage of being non-invasive and, often, inexpensive. For almost 
all of these techniques, there are conflicting data, and not one tech-
nique has proven beneficial in patients with structural heart disease. 
Moreover, studies have varied in their reporting of sudden arrhyth-
mic death vs. total mortality. Among the risk predictors shown to 
have value are QRS widening and fragmentation, QT prolongation, 
T-wave abnormalities, and ventricular ectopy. Although the prognos-
tic value of each ECG parameter in isolation is limited, in combination 
with additional ECG, imaging, and genetic testing, these parameters 
can contribute to effective risk stratification.
QRS
QRS prolongation has been associated with all-cause mortal-
ity in heart failure patients, implantable cardioverter-defibrillator 
(ICD) shocks, and inducibility of sustained VT. QRS prolongation 
in patients on Class IC antiarrhythmic drugs is a predictor of pro-
arrhythmia, and should be monitored, particularly during exercise. 
QRS prolongation predicts risk in patients with myotonic dystrophy 
and in Brugada Syndrome. Additional prognostic information from 
the QRS is obtained from the signal-averaged ECG, which amplifies 
the QRS, averages multiple complexes to reduce noise, and filters 
out the T-wave in order to detect late potentials, and provides evi-
dence of slow conduction substrate that associates with risk of re-
entry tachyarrhythmias.17 The signal-averaged ECG has been used 
to detect risk of ventricular arrhythmias in post-infarction patients, 
arrhythmogenic cardiomyopathy, and Brugada Syndrome. Although 
its specificity is limited, its negative predictive value is high, particu-
larly in survivors of inferior wall myocardial infarction. The signal-av-
eraged ECG is not useful in patients with underlying bundle branch 
block. QRS fragmentation, which includes abnormally notched nar-
row and wide QRS complexes, is associated with the presence of 
myocardial scar and is also associated with mortality in patients with 
cardiomyopathy and with Brugada Syndrome.32 The presence of an 
unprovoked type 1 Brugada Syndrome pattern is associated with in-
creased risk as is discussed later in the document.
QT interval
Measurement of the QT interval can be complicated by QRS pro-
longation and by the need to correct for heart rate, as has been 
described elsewhere.33 Despite these limitations, prolongation of 
the heart rate-corrected QT interval (QTc) has been associated with 
mortality in several population studies.34,35 In congenital long QT 
syndrome (LQTS), the length of the QT interval is a major predic-
tor of risk of cardiac events, including sudden cardiac death (SCD). 
When initiating QT-prolonging drugs such as sotalol or dofetilide, a 
QT interval of 500 milliseconds or higher should prompt reduction 
or discontinuation of the offending drug(s).
QT dispersion
This measure of ventricular repolarization heterogeneity is typi-
cally defined from the 12-lead ECG as the QTmax − QTmin. It has been 
used to predict a wide variety of events, including ventricular pro-
arrhythmia, VTs, although the sensitivity, specificity, and accuracy 
are poorly defined and highly dependent on the patient population 
studied.36
T wave
T wave inversions are common and may be non-specific or may 
signal important abnormalities such as ischaemia or hypertrophy. 
Widespread deep T wave inversions in combination with QT pro-
longation, such as may occur in acute stress cardiomyopathy, can 
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be associated with torsades de pointes. Abnormal T wave notching 
can be a clue to abnormal repolarization and is often seen in patients 
with QT prolongation. Computerized T-wave analytic techniques 
such as principal component analysis, T-wave residuum, flatness, 
asymmetry, and notching have been developed in an effort to detect 
and quantify abnormal repolarization and may have particular value 
in identifying patients with LQTS.37,38 Moreover, it has been shown 
that adding T-wave morphology characterizations to age, gender, 
and QTc in a support vector machine model can improve LQTS diag-
nosis.39 However, these additional analytic techniques are not used 
in routine clinical practice.
The Tpeak-end interval, measured from the peak to the end of 
the T-wave, thought to reflect heterogeneity of repolarization in 
the heart, has been associated with arrhythmic risk in various pop-
ulations.40 However, considerable controversy remains as to how it 
should be measured and applied.41
T-wave alternans is a beat-to-beat alternation of T wave mor-
phology. When seen with the naked eye, it usually accompanies 
marked QT prolongation and is a harbinger of immanent torsades 
de pointes. Analysis of more subtle T-wave alternans has been 
used for assessing abnormal and heterogeneous repolarization to 
predict mortality and arrhythmic risk. Abnormal microvolt T-wave 
alternans assessed using the spectral method during graded ex-
ercise has a high negative predictive value and has been used to 
identify a subgroup of patients with reduced ejection fraction who 
are not likely to benefit from defibrillator implantation.18 Microvolt 
T-wave alternans analysis cannot be performed when the rhythm 
is AF, and patients with ventricular pacing have not been studied 
extensively.
Early repolarization
Early repolarization pattern, highly prevalent in the overall popula-
tion, defined as an elevation of the J point of at least 0.1 mV, may 
occur in the anteroseptal or inferolateral leads. In 2008, Haissaguerre 
reported an association of inferolateral early repolarization with in-
creased risk of idiopathic ventricular fibrillation (VF) in a case–control 
study42 and subsequently confirmed in other case–control studies. 
Exercise testing or isoproterenol testing improved the pattern of re-
polarization, and the pattern was accentuated with exposure to beta-
adrenergic blockers. In a meta-analysis of population-based studies, 
inferolateral early repolarization was associated with increased 
risk of arrhythmic death, but the risk was still quite low in general 
(70/100 000 patient-years).43 It appears that individuals at highest 
risk have early repolarization in multiple (especially inferior) leads, 
with high voltage (at least 0.2 mV), and with notching or horizontal/
down-sloping ST segments. Early repolarization is especially preva-
lent in young men, particularly young black men, and in athletes.44 
Because the absolute risk of arrhythmic death is so low, asympto-
matic individuals with early repolarization, even those with higher risk 
ECG patterns, do not require further evaluation except when there is 
a strong family history of sudden cardiac death or when the J point 
elevation is associated with Brugada syndrome (discussed later in this 
document) or short QT syndrome (SQT).
2.2.4 | Ambulatory electrocardiographic monitoring
In 1984, Bigger et al. showed that ventricular ectopy recorded on 
a Holter monitor, especially when combined with a low left ven-
tricular ejection fraction (LVEF), predicted a higher risk of mortal-
ity in post-infarction patients compared to those without ectopy.45 
Non-sustained VT is also associated with increased risk in patients 
with arrhythmogenic and hypertrophic cardiomyopathy (HCM). 
Other data that can be extracted from ambulatory monitoring in-
clude heart rate, heart rate variability, and heart rate turbulence 
measurements, which can predict mortality risk at least in ischae-
mic cardiomyopathy, but have not been incorporated into clinical 
practice.19,46
2.3 | Imaging
2.3.1 | Risk assessment of ventricular tachyarrhyth-
mia using imaging modalities
Evaluation for the presence of structural heart disease (SHD) is im-
portant for patients suspected of being at risk for sudden cardiac 
death. Left ventricular ejection fraction remains the key independ-
ent parameter for risk stratification of sudden cardiac death and to 
guide implantation of an ICD.47,48 Randomized controlled trials have 
shown a survival benefit from ICDs in patients with SHD and an EF 
≤35%.54–56 Although EF is currently the only proven imaging mo-
dality demonstrated to risk stratify for sudden cardiac death, only 
1%-5% of patients with ICDs, implanted based upon a low EF, require 
therapies each year and the large majority of patients who receive 
ICDs will not have ICD therapies over the 3-year period after im-
plantation.57,58 In addition, up to 70% of all sudden cardiac deaths 
in the community occur in individuals with EF >35%.58–60 Although 
Imaging (echo, computed 
tomography (CT), magnetic 
resonance imaging (MRI), 
perfusion) Class References
Echocardiography should be used 
to evaluate EF for risk assessment 
for primary prevention of sudden 
cardiac death and the presence 
of structural heart disease. 
Alternatively, MRI or cardiac CT 
can be used.
47,48
Cardiac MRI is useful in assessing 
aetiology-driven risk of VT and for 
the presence of scar or myocardial 
inflammation.
49–51
Cardiac positron emission 
tomography may be useful for the 
assessment of aetiology-driven 
risk of ventricular arrhythmias and 
the presence of scar or myocardial 
inflammation in patients without 
CAD.
52,53
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the Efficacy of ICDs in Patients with Non-ischaemic Systolic Heart 
Failure (DANISH) trial showed that primary prevention ICD in the 
setting of severe non-ischaemic cardiomyopathy did not reduce 
all-cause mortality in patients on optimal medical therapy for heart 
failure, ICD implantation was associated with a 50% reduction in ar-
rhythmic death. Of note, within this non-ischaemic cardiomyopathy 
population, younger patients (<68 years old) experienced a mortality 
benefit of 36% if treated with an ICD.61
Ejection fraction is most readily evaluated with echocardiogra-
phy (recommendation level: green), given both lower cost, availabil-
ity of equipment, and available expertise; however, cardiac MRI or 
CT can also be used to evaluate EF and SHD, particularly if obtained 
in combination of other assessment aims, such as CAD or if there 
is controversy over the quantified EF with echo (recommendation 
level: green). The imaging modality used to estimate EF has not been 
shown to determine benefit from ICD.48
Additional parameters beyond EF remain to be tested in large 
studies. Cardiac MRI with late gadolinium enhancement (LGE) can 
provide important prognostic information and may allow for more 
accurate assessment of scar. Presence and location of scar can 
portend a higher risk of sustained VT.49–51,62,63 In a study of 452 
non-ischaemic cardiomyopathy patients with New York Heart 
Association Class II or II and EF <35%, ICD implantation was only 
associated with reduced mortality in the population that had pres-
ence of scar on cardiac MRI.64 Cardiac positron emission tomogra-
phy (PET) may elucidate areas of inflammation which may identify 
inflammatory cardiomyopathies and sarcoidosis, a condition that 
is associated with higher risk of ventricular arrhythmias in patients 
without CAD (increased F-2-fluorodeoxyglucose uptake) or can 
be used to identify sympathetic denervation (carbon-11-metahy-
droxyephedrine imaging) or regions of inflammation. Greater sym-
pathetic denervation on PET in a prospective study of ischaemic 
cardiomyopathy patients was a better predictor of ICD shocks than 
EF.65 Uptake of iodine-123 meta-iodobenzylguanidine (MIBG) to 
evaluate heart to mediastinum ration (H/M ratio) has shown mixed 
results in predicting arrhythmic death with some studies suggesting 
additional prognostic benefit for this parameter, while others have 
not demonstrated additional value.66,67 Importantly, the value of 
these additional parameters in determining risk of sustained VT, VF, 
or benefit from ICD in various population remains to be clarified. 
Finally, routine use of viability assessment using PET to guide re-
vascularization in order to reduce risk of SCD remains an area of 
investigation. In patients with an EF <35% and CAD amenable to 
revascularization, routine use of PET to guide revascularization was 
not beneficial in reducing overall mortality.68
2.3.2 | Imaging modalities for atrial arrhythmias
Echocardiography (transthoracic or transoesophageal) is a valuable 
tool in patients who present with atrial arrhythmias, specifically 
atrial flutter and AF, to evaluate for the presence of structural heart 
disease, left atrial enlargement, and valvular heart disease in order 
to better define treatment options. Cardiac MRI or CT may also 
be used if images obtained at echocardiography are not reliable. 
However, routine use of echocardiography, including atrial strain or 
atrial function in patients who do not have atrial arrhythmias to as-
sess risk for the development of AF or atrial flutter is not warranted, 
unless other structural cardiac abnormalities are suspected.
2.4 | Invasive electrophysiological study
Invasive electrophysiological 
study (EPS) Class References
EPS is indicated in patients with 
syncope and previous myocardial 
infarction, or other scar-related 
conditions when syncope 
remains unexplained after non-
invasive evaluation.
69
EPS may be considered in patients 
with syncope and asymptomatic 
sinus bradycardia, in a few 
instances when non-invasive 
tests (e.g. ECG monitoring) have 
failed to show a correlation 
between syncope and 
bradycardia
70–72
EPS may be considered in patients 
with EF ≤ 40%, without a primary 
prophylactic ICD indication, and 
non-sustained VT in ischaemic 
cardiomyopathy (MUSTT criteria) 
to ascertain the presence of 
sustained VT events.
73
EPS may be helpful in patients 
with syncope and presence of a 
cardiac scar, including those with 
a previous myocardial infarction, 
or other scar-related conditions, 
when the mechanism of syncope 
remains unexplained after non-
invasive evaluation.
66,70,71,73
EPS may be considered in patients 
with syncope and bifascicular 
block, when the mechanism of 
syncope remains unexplained 
after non-invasive evaluation.
67,70,71,74
EPS may be considered for risk 
stratification of SCD in patients 
with tetralogy of Fallot who have 
one or more risk factors among 
LV dysfunction, non-sustained 
VT and QRS duration exceeding 
180 ms.
67,70,71,74
EPS may be considered in patients 
with congenital heart disease 
and non-sustained VT to 
determine the risk of sustained 
VT or identify SVT that could be 
ablate.
67,70,71,74
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Invasive electrophysiological 
study (EPS) Class References
EPS may be considered in 
asymptomatic patients with 
spontaneous type 1 Brugada 
ECG pattern, or drug-induced 
type 1 ECG pattern and 
additional risk factors.
75–77
EPS is not recommended for 
additional risk stratification in 
patients with either long or short 
QT, catecholaminergic VT or 
early repolarization.
70,71
EPS is not recommended for risk 
stratification in patients with 
ischaemic or non-ischaemic 
dilated cardiomyopathy 40 
(DCM) who meet criteria for ICD 
implantation.
70,71
Currently, there are a few indications to perform an electro-
physiological study (EPS) to further assess the risk of arrhythmias 
in at-risk cardiac patients. Such patients include those with struc-
tural heart disease, LVEF >35%, pre-syncope, syncope, palpita-
tions, or markedly abnormal ECG suggesting severe conduction 
disease. These patients can be considered for an EPS to assess 
the risk of ventricular arrhythmias and sudden cardiac death to 
decide on need of an ICD, or to identify conduction disturbances 
or supraventricular tachycardias that can be treated with ablation 
or pacing.70,71
Patients with ischaemic cardiomyopathy without a primary 
indication for an ICD, EF ≤40%, and non-sustained VT on am-
bulatory cardiac monitoring are candidates for an EPS according 
to the findings in the MUSTT trial,73 in which, 35% of patients 
with inducible sustained VT had a significantly lower risk of 
death with an ICD.66 The MADIT trial initially also utilized an 
EPS in post-MI patients with an EF ≤30%, and non-sustained VT 
events to implant an ICD, and showed survival benefit with the 
ICD.54 However, MADIT-II subsequently eliminated the need for 
an EPS in post-MI patients with an EF ≤30% and similarly showed 
the life-saving benefit of the ICD in a broader patient cohort.55 
Therefore, post-MI patients with an EF ≤30% do not currently 
need to undergo an EPS to guide decisions on whether to implant 
an ICD.
In patients with heart failure and EF ≤35%, an EPS is not rec-
ommended for risk assessment for the decision on ICD indication. 
Some centres perform an EPS for inducibility to better characterize 
induced, sustained VT events, and their response to antitachycardia 
pacing (ATP), which may potentially help to tailor ICD programming. 
Furthermore, in patients who have syncope of uncertain origin, an 
EPS could identify ventricular arrhythmias or document electrical 
conduction disorders.67,70,71,74
In the case of channelopathies, there is no indication for an EPS, 
except for Brugada syndrome. In Brugada syndrome, EPS may be 
useful in asymptomatic patients with spontaneous or drug-induced 
type 1 pattern, especially when there is a family history of sudden 
death.75–77
2.5 | Implantable loop recorders
Implantable cardiac devices Class References
An ILR is indicated in the 
evaluation of patients with 
infrequent recurrent syncope 
of uncertain origin especially 
when ambulatory monitoring is 
inconclusive
78–80
An ILR is indicated in patients 
with syncope and high-
risk criteria in whom a 
comprehensive evaluation did 
not demonstrate a cause of 
syncope or lead to a specific 
treatment, and who do not 
have conventional indications 
for primary prevention ICD or 
pacemaker.
78–80
An ILR can be considered in 
patients with palpitations, 
dizziness, pre-syncope, 
frequent premature ventricular 
complexes (PVCs)/non-
sustained VT, and in those with 
suspected AF, and following 
AF ablation.
78–80
2.5.1 | Implantable loop recorder to diagnose 
unexplained syncope/atrial fibrillation with 
cryptogenic stroke
The implantable loop recorder (ILR) provides long-term continuous 
monitoring and improves the diagnosis in patients with unexplained 
syncope.81 In a meta-analysis of 49 studies that included 4381 par-
ticipants, the diagnostic yield for the detection of arrhythmogenic 
syncope was 26.5%.78 Moreover, the CRYSTAL-AF trial80 revealed 
that the ILR can detect subclinical AF following cryptogenic stroke. 
Still, any benefit of these findings needs to be confirmed in large 
randomized trials. Early use of the ILR has been advocated by the 
European guidelines82 and in the American guidelines following in-
conclusive non-invasive monitoring.83 The indications for ILR have 
been expanded in the current guidelines (Table 2).
2.5.2 | Implantable loop recorder to diagnose 
atrial and ventricular arrhythmia events
While the ILR can be useful to detect atrial and ventricular arrhythmias, 
a large cohort study indicated that most of the current use of ILRs is pri-
marily in patients with unexplained syncope (84%), followed by palpita-
tions (13%), and suspected AF (12%).79 Another smaller study specifically 
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studying the risk of SCD and arrhythmias in patients with haemodialysis, 
found that 20% of these patients had SCD or bradyarrhythmia events 
necessitating pacemaker implantation, and 33% of these patients had 
an arrhythmic endpoint. Interestingly, the median time to event was 
2.6 years, confirming the need for long-term monitoring. Surprisingly 
however, bradyarrhythmias were very commonly diagnosed in this co-
hort suspected to be at high risk for ventricular arrhythmias and sudden 
cardiac death.84 Further studies are needed to establish the role of ILR 
in risk stratification.
2.6 | Wearables/direct to consumer
Wearables/direct to 
consumer Class References
Wearables may provide 
diagnostic data that 
contribute to disease 
detection and management 
when integrated into 
the clinical context and 
physician judgement
85,86
The direct to consumer or wearable technology market, com-
prised of devices that monitor physiological parameters such as heart 
rate and sleep pattern, is anticipated to grow to 929 million connected 
devices by 2021.87 These devices encompass wristbands, glasses, in-
ear monitors, chest straps, and smart phone-enabled recording elec-
trode systems or electronic shirts, with varying capacity to monitor 
heart rate, heart rhythm, blood pressure, physical activity, respiratory 
rate, blood glucose, and sleep patterns.88–90 For heart rate monitor-
ing, most wearable devices use photoplethysmography (PPG) tech-
nology, meaning they are inherently less accurate than conventional 
electrocardiography monitoring techniques. Accuracy of various de-
vices varies, with correlation to reference standard ECG monitoring 
ranging from 0.76 to 0.99.91 Recent advances in wearable ECG acqui-
sition include use of direct electrode recording that represents a reg-
ulatory approved medical device generating a lead I like rhythm strip, 
blurring the lines between consumer and medical devices.92
A growing body of evidence suggests that these technologies 
can be harnessed to facilitate arrhythmia detection in the appro-
priate context. Although marketed as consumer devices, many 
wearable devices may generate health data comparable to that of 
medical grade ECG monitors, with several devices migrating to ap-
proved medical use.85 Despite this promise, there are clear concerns 
regarding accuracy, particularly false positives in asymptomatic pa-
tients where device-based alerts can raise unwarranted concern 
and generate low yield screening for disease, with associated costs. 
Wearable technologies represent an important frontier in health 
evaluation, with the potential to provide readily accessible health 
data for large segments of the population, including those not cap-
tured by conventional monitoring techniques. Though intended for 
personal use focused on health promotion and physical activity, 
wearable technologies promise to invert the traditional paradigm of 
healthcare delivery, with data collection and health queries often ini-
tiated by consumers and not providers. Providers may see wearables 
as accessible risk stratification tools for detection of AF in high-risk 
cohorts (such as high CHADS2-VASC2 score patients), and patients 
may equally present for evaluation after device-based observations 
that call into question whether they are at risk. The confluence of 
these factors is illustrated in the recently presented Apple Heart 
Study, wherein 419 297 participants were recruited in only 8 months 
to participate in an AF screening study that deployed a PPG-based 
algorithm followed by a 7-day patch if AF was suspected.93 Using a 
complex tachogram algorithm, 2126 individuals were sent irregular 
pulse notifications and prompted for a telemedicine visit and 7-day 
ECG patch. The authors reported a PPV of 84% for each irregular 
pulse notification, and 71% for each irregular tachogram. The bur-
den of notifications and the performance of the technology showed 
promise to inform AF detection in the broader public. Similarly, the 
Huawei Heart Study evaluated 187 912 individuals that used smart 
devices to monitor their pulse rhythm, with notification of suspected 
AF in 424 participants, with a strong relationship between advanc-
ing age and detecting AF. The predictive value of the algorithm in 
the 62% of notified participants that pursued medical evaluation was 
promising (87%).94
TA B L E  2   High-risk and low-risk criteria for syncope at initial 
evaluation (Adapted from 2018 ESC Guidelines for the diagnosis 
and management of syncope82)
Syncopal events
Low-risk
Associated with prodrome typical or reflex syncope (e.g. light-
headedness, feeling of warmth, sweating, nausea, vomiting)
After sudden unexpected unpleasant sight, sound, smell, or paina 
After prolonged standing or crowed, hot places
During a meal or postprandial
Triggered by cough, defaecation, or micturition
With head rotation or pressure on carotid sinus (e.g. tumour, 
shaving, tight collars)
Standing from supine/sitting position
High-risk
Major
New onset of chest discomfort, breathlessness, abdominal pain, or 
headache
Syncope during exertion or when supine
Sudden onset palpitation immediately followed by syncope
Presence of structural heart disease especially left ventricular 
dysfunction and/or history of myocardial infarction
Minor (high-risk only if associated with structural heart disease or 
abnormal ECG):
No warning symptoms or short (<10 s) prodrome
Family history of sudden cardiac death at young age
Syncope in the sitting position
ECG, electrocardiogram; VF, ventricular fibrillation.
aSudden loud sounds (as an alarm clock) may trigger VF in some long QT 
syndrome patients. 
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Studies evaluating PPG-based wearables in conjunction with 
machine-learning algorithms have shown promise in arrhythmia 
detection, such as AF.86 Studies to date have not focused on ven-
tricular arrhythmia detection. Future wearables will benefit from 
improved reliability and accuracy, collect additional health and 
fitness parameters, support chronic disease management, and 
provide real-time connectivity and feedback that may supplant 
conventional medical monitoring. Wearables have the potential 
to become truly disruptive in our healthcare sector, with large 
segments of the population accessing cardiac monitoring that the 
physician must interpret. Currently, we have no data on how the 
information provided by PPG-based wearables will affect manage-
ment and outcomes of patients, or how risk scores derived in other 
populations such as the CHA2DS2-VASc score apply in these previ-
ously undetected subjects.
2.7 | Biomarkers, tissue, genetics
Biomarkers, tissue, genetics Class References
Genetic testing should 
be considered in several 
inherited arrhythmic diseases 
associated with an increased 
risk of ventricular arrhythmia 
and SCD
95–97
MRI with LGE to detect 
fibrosis and scar may be 
useful in assessing the risk 
of arrhythmic events in AF 
patients and patients with 
cardiomyopathies
98–100
Plasma NT-proBNP may be 
useful in differentiating 
patients with higher vs. lower 
burden of AF
101–105
Plasma CRP or other 
inflammatory markers may be 
useful in risk assessment, for 
identifying individuals with 
increased risk of future AF 
and for identifying individuals 
with high degree of atrial 
fibrosis
106–108
The use of biomarkers, tissue biopsy, and genetic assessment 
can be used for risk assessment in patients suspected of specific 
arrhythmias or syndromes. The utility of using these tools broadly 
spans determining arrhythmic risk, refining a clinical diagnosis and 
estimating prognosis.
2.7.1 | Biomarkers
Cardiac myocytes express and secrete natriuretic hormones that have 
a central function on blood pressure regulation, blood volume, and 
plasma sodium balance. Levels of B-type natriuretic peptide (BNP) and 
its stable N-terminal peptide pro-BNP (NT-proBNP) are increased in 
AF.101 AF burden has been shown to be associated with increased NT-
proBNP.102 In a large meta-analysis consortium, BNP and C-reactive 
protein (CRP) associate with AF but only BNP was superior to well-
known clinical variables in AF risk prediction.103 Inflammatory pro-
cesses and fibrosis are central to pathogenesis of AF,106,109 and the 
inflammatory marker CRP is associated with longer AF duration and 
atrial remodelling.110 CRP levels are elevated in patients with perma-
nent AF compared to persistent AF patients and are predictive of re-
current AF after catheter ablation,111,112 indicating that CRP levels can 
be used to identify AF subtypes and evaluate prognosis. Higher levels 
of CRP correlated to an increased risk of developing AF in general and 
after acute myocardial infarction.107,113 Similarly, the plasma protein 
YKL-40 may have diagnostic and prognostic use in AF patients108 be-
cause plasma serum chondrex (YKL-40) is associated with atrial fibrosis 
severity in patients with lone AF.114 Patients who experience recur-
rent AF following ablation have significantly increased YKL-40 base-
line levels, although plasma YKL-40 is not an independent predictor 
of recurrent AF.108,115 Increasing levels of YKL-40 have been shown to 
associate with a two-fold increased risk of future AF.116 Other simple 
AF biomarkers include body weight and blood pressure, which are also 
major intervention targets.117–122
2.7.2 | Tissue diagnostics
Tissue diagnostics can be beneficial to differentiate various infiltra-
tive myopathic processes that can contribute to the risk for arrhyth-
mic events. Fibrosis and scarring are well-recognized substrates for 
arrhythmia both in atria and ventricles.109 Fibrosis may be assessed in 
atria as well as in ventricular myocardium and its quantification can 
be used in evaluating the risk of arrhythmia in AF and cardiomyopa-
thies.98,99 Specific patterns of scarring can assist in refinement of the 
diagnosis for infiltrative myopathies, hypertrophic cardiomyopathy, 
sarcoidosis, arrhythmogenic cardiomyopathy, and amyloidosis. The 
development and validation of advanced imaging techniques including 
bio-metabolic imaging (sarcoid), and contrast enhanced cardiac MRI 
(amyloid) have largely replaced the need for invasive diagnostics.
2.7.3 | Genetics
The majority of clinically applicable genetic testing is intended 
to be driven by phenotype and the pre-test probability of spe-
cific diagnosis determines the utility of genetic investigation.95 
Due to incomplete penetrance of genetic arrhythmia syndromes, 
harbouring a genetic variant with known pathogenicity is almost 
never solely enough to meet diagnostic criteria for a particular 
syndrome.123
For LQTS, part of the diagnostic framework (along with the 
ECG biomarker of QT prolongation) can include a positive ge-
netic test.123 Moreover, understanding the genetic diagnosis is 
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important for treatment and prognostication. For example, pa-
tients with Jervell and Lange-Nielsen and Timothy Syndrome pa-
tients (LQT8) have more malignant clinical courses,124,125 and for 
LQT1 the arrhythmic risk depends partly on which region of the 
channel the mutation affects.126 In catecholaminergic polymor-
phic ventricular tachyarrhythmia (CPVT),127 genetic testing of 
suspected individuals has a moderately high yield.95 Identification 
of an at risk first-degree relative of a CPVT affected individual is 
essential due to the high penetrance but more so the lethality of 
this syndrome.123,128 Similar to LQT1, CPVT due to RYR2 muta-
tions may have some degree of risk depending on where in the ry-
anodine receptor the mutation falls.129 Brugada syndrome can be 
particularly difficult to clinically diagnose and the utility of genetic 
testing for improving diagnosis is poor. For patients who are clini-
cally diagnosed with Brugada Syndrome the yield of genetic test-
ing is ~30%,130 the majority of whom harbour SCN5a mutations, 
a gene associated with a plethora of arrhythmia syndromes.131,132 
Genetic testing can be useful for family members of an appropri-
ately genotype identified proband but is not recommended in the 
absence of a diagnostic ECG.95 Using genetics as part of diagnos-
tic criteria for arrhythmogenic cardiomyopathies will be discussed 
later in the document. Lastly, genetics in AF is a developing area, 
but certain primary electrical sudden death syndromes have in-
creased AF association as discussed in Patients with inherited 
rhythm disease (long QT syndrome/short QT syndrome/catechol-
aminergic polymorphic ventricular tachyarrhythmia/Brugada syn-
drome) section. For families with a substantial number of AF cases 
or in early onset AF,133–136 genetic testing can be considered but 
the yield is low.
2.8 | Artificial intelligence
Machine learning is a broad term of artificial intelligence derived 
from the extraction of patterns from large data sets. The marriage 
with healthcare analytics and decision processes has been rapidly 
forwarded with computerized medical records and the creation of 
large data warehouses.
A deep neural network was created to analyse raw ECG data from 
an ambulatory heart monitor and classify it into 12 categories based 
upon the presence of arrhythmia. Machine learning performed very 
well with an average under the reviewer operating characteristic curve 
(ROC) of 0.97 and an average F1 score (mean of the PPV and sensi-
tivity) of 0.837; a score better than an average cardiologist (0.780).137
Machine learning has been applied to standard ECG character-
istics in sinus rhythm to predict incident AF using the eight inde-
pendent ECG leads (leads I, II, V1-6) through a convolutional neural 
network.138 The ROC area under the curve for the detection of AF 
was 0.87 (0.86-0.88) using the internal validation dataset and 0.87 
(0.86-0.88) using the testing dataset.
In an analysis of the Atrial Fibrillation Prediction Database, a 
machine learning approach based upon heart rate variability pre-
dicted onset of AF with sensitivity of 100%, specificity of 95.6%, and 
accuracy of 96.2%.139 Machine learning based upon ECG character-
istics identified left ventricular dysfunction with an area under the 
curve of 0.93, sensitivity of 86.3%, and specificity of 85.7% including 
risk of left ventricular dysfunction in those without.140
Machine learning has shown accuracy in predicting mortality and 
risk stratification of patients with CAD.141 Machine learning has also 
been shown to accurately discriminate between athletic hearts com-
pared to hypertrophic cardiomyopathy hearts.142 Machine learning 
has great potential in this area of risk assessment because of the 
large amount of data contained in the large ECG and clinical datasets 
available to determine rules.
3  | HOW TO A SSESS RISK FOR ATRIAL 
FIBRILL ATION IN SPECIFIC POPUL ATIONS
3.1 | Patients of advanced age
There is agreement that the prevalence of AF in the general popula-
tion in the Western world is in the order of 1%-2%.143–145 It is esti-
mated that in 2010 there were 33.5 million people in the world with 
AF of which 20.9 million were men and 12.6 million were women.146 
During the past 20 years, the age-adjusted prevalence rates of AF 
increased for both men and women and similarly the correspond-
ing incidence rates have increased.146–150 Age is a major risk factor 
for the development of AF and in persons younger than 55 years 
a prevalence of AF around 0.5% is seen whereas in persons older 
than 85 years AF prevalence is around 15% (Figure 1).144 A step-
wise increase in AF prevalence with increasing age has been found 
in several studies.152,153 Studies in a multi-ethnic cohort from the 
United States has shown large variation in AF prevalence among var-
ious race-ethnicity groups in which AF associated hospitalizations 
were lower in Hispanics, Chinese, and Black Americans compared to 
White Americans.153 The predominant contributor to the increasing 
AF prevalence is our aging populations, more widespread use and 
availability of screening tools, and improved treatment for various 
heart diseases that enhance longevity.
Among AF patients, those aged younger than 65 years are in gen-
eral healthier than those older than 65 years.154 Life time risks of AF 
in 55-year-old subjects without a history of AF have been found to 
be 20%-24% in the Rotterdam study155 but considerably higher at 
37% in the Framingham study.134 The lifetime risk of AF in Asians 
older than 20 years (1 in 6 for men and 1 in 7 for women; i.e. 14%-
17%) was lower than the risk reported from Western countries.156
The incidence rates, prevalence, and lifetime risk of AF are 
higher for men than women. Despite this, the absolute number of 
women with AF exceeds the total number of men with AF because 
women live longer than men.144 Women have their first episode of 
AF about 5 years later than men and less commonly have lone AF.144 
In general, women with AF are more likely to have hypertension or 
valvular heart disease compared to men.144 Women often present 
with atypical symptoms related to AF (Figure 2). On the other hand, 
compared to men, women are less likely to have asymptomatic AF, 
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they have a higher symptom burden, they have higher average heart 
rate during AF and more often longer lasting episodes of AF.144 These 
factors contribute to the observation that women are more likely to 
contact their physician due to AF-related symptoms compared to men.
Conflicting results exist with respect to risk of stroke secondary 
to AF and its prognosis in women compared to men.157–159 There 
does not seem to be a gender difference with respect to develop-
ment of dementia secondary to AF, although women have higher 
rates of dementia than men in general.145,157
Since both AF and stroke are highly associated with age and 
stroke may occur as a complication of AF it seems reasonable 
to consider screening for this arrhythmia in elderly popula-
tions. Several studies are ongoing and expected to be finalized 
within the next couple of years. These studies are expected to 
guide us with respect to cost-effectiveness of these screening 
strategies.
3.2 | Patients with heart failure
Due to common risk factors like age, hypertension, diabetes, obe-
sity, and sleep apnoea, AF and HF are intricately linked and share 
common pathophysiologic mechanisms. Atrial fibrillation occurs in 
more than half of individuals with HF and presence of both car-
ries greater mortality risk compared with those without either 
condition.167
In the particular case of cancer treatment, HF is also a common 
consequence of cardiotoxicity associated with some chemothera-
peutic agents, including anthracyclines, human epidermal growth 
factor receptor 2 (HER2), and proteasome inhibitors. In this setting, 
isolated cases of AF have been reported. Even if the exact mech-
anism of these arrhythmias induced by such drugs remains largely 
F I G U R E  1   A depiction of the atrial 
fibrillation prevalence distribution found 
by each study published to date.151 This 
depiction uses the sex-specific average 
rates of AF prevalence, grouped by age. 
The thick line represents average AF 
prevalence rates by age group, as derived 
from a pooled analysis of the individual 
studies weighted by sample size. (Adapted 
from Andrade et al. Circ Res 2014.) AF, 
atrial fibrillation.
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Investigations needed to assess 
risk for AF in patients with heart 
failure Class References
A careful evaluation of clinical 
characteristics known to be 
associated with increased risk 
for AF should be performed
160
Frequent interrogation or remote 
monitoring of stored arrhythmia 
episodes in device implanted HF 
patients should be performed in 
order to diagnose AF and allow 
its early management
161
Investigations needed to assess 
risk for AF in patients with heart 
failure Class References
Echocardiography is useful 
in identifying cardiac 
characteristics associated with a 
higher risk for AF
162
Cardiac MRI may be considered 
in identifying degree of atrial 
fibrosis and scar
163
Use of biomarkers may be 
considered for identifying 
individuals with increased risk 
of future AF and for identifying 
individuals with high degree of 
atrial fibrosis
107,164,165
Searching for common genetic 
variants associated with AF risk 
by genetic molecular analysis 
has not been found to be useful 
in a routine clinical setting
166
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unknown, it seems plausible that the negative effect on the cardiac 
systolic function also plays a central role.168
Given the deleterious effects of AF in HF patients, significant 
interest has been directed to risk factors predicting the development 
and progression of this arrhythmia (Figure 3).
3.2.1 | Clinical risk factors
Older age and male gender are associated with a higher risk of de-
veloping AF.160 Diabetes confers a 1.4- to 1.6-fold higher risk for 
AF.160 Because of its high prevalence in the general population, hy-
pertension is responsible for more AF in the population (14%) than 
any other risk factor.160 Obesity and sleep apnoea are independent 
risk factors for AF.169 AF incidence also increases in case of renal or 
thyroid dysfunction.170,171
With regard to HF and the type of underlying heart disease, 
prevalence of AF increases significantly with the severity of HF 
symptomatology. Among the valvular diseases, the left-sided valve 
stenoses have the highest prevalence rates of AF. In addition, the 
presence of CAD or hypertrophic cardiomyopathy is a significant 
risk factor for incidence and progression of AF.172 Finally, in congen-
ital heart disease patients, substantial AF rates appear decades be-
fore their onset in the general population.173
3.2.2 | Electrocardiography
Electrocardiogram-derived variables, such as the PR interval, ECG-
based left ventricular hypertrophy (LVH), P wave indices like P wave 
duration, area, and terminal force have been used in various AF pre-
diction models but their additive value over other clinical risk fac-
tors is minimal.174 Short duration Holter monitoring is not useful for 
AF detection in asymptomatic patients. Longer duration monitoring 
with external or implantable loop recorders may help when parox-
ysmal AF is suspected. In addition, frequent interrogation or remote 
monitoring of Holter memories in device implanted HF patients is 
mandatory in order to diagnose AF and allow its early management.161
3.2.3 | Biomarkers
Markers of inflammation (high-sensitivity CRP, fibrinogen), atrial 
overload (atrial and B-type natriuretic peptides), myocardial ischae-
mia (high-sensitivity troponin T and I), cardiac fibrosis (galectin-3), 
and others (soluble ST2, growth differentiation factor-15), have 
been studied to predict AF incidence.165 Of these, only natriuretic 
peptides have consistently demonstrated added predictive value be-
yond information on clinical variables.164,165
3.2.4 | Imaging
Many echocardiographic variables have been associated with a sig-
nificantly higher AF recurrence rate. Possibly, left atrial volume is 
superior to left atrial diameter in predicting progression to persistent 
AF. Speckle left atrial strain and stiffness index can also predict the 
maintenance of sinus rhythm after cardioversion for AF.162
Concerning MRI, the amount of left atrial enhancement quanti-
fied on MRI with LGE may be helpful to predict progression of AF,163 
but the reproducibility of such findings remains controversial.
3.2.5 | Genetics
A family history of AF in a first-degree relative independently in-
creases AF risk two-fold.175 Recent research has identified several 
common genetic variants associated with the risk of AF.136 Further 
studies are required to evaluate whether genetic information im-
proves our ability to predict AF on top of clinical variables.
Risk assessment of AF in patients with HF can be carried out 
at first by considering the clinical features, comorbidities, and 
F I G U R E  2   Sex differences in 
symptoms related to atrial fibrillationy144 
(Adapted from fig. 2 in Andrade et al. 
Can J Cardiol 2018). [Colour figure can be 
viewed at wileyonlinelibrary.com]
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underlying aetiologies. It can be further refined by more sophisti-
cated investigations.
3.3 | Patients with obesity, hypertension, diabetes, 
sleep apnoea, or structural heart disease
The assessment of underlying AF in people at higher risk for AF can 
be considered from opportunistic perspective, or the consideration of 
clinical risk prediction tools.180 Many patients with common conditions 
that may predispose to AF, such as obesity, sleep apnoea, hyperten-
sion, or SHD should or would be attending specialist clinics for their as-
sessment and/or follow-up. Hence, an opportunistic strategy of pulse 
palpation and clinical assessment (e.g. symptoms) followed by appro-
priate ECG monitoring to confirm AF would be an appropriate and cost 
effective method for screening.181 In general, clinical scores have been 
less useful as most only have modest predictive value for identifying 
the population at risk; ultimately, these patients would also require 
their AF documented. A strategy of using risk scores to target high-risk 
patients for more intense screening efforts merits consideration.
The systematic review by Allan et al.176 found that in relation to 
the relative risk of incident AF:
• For every 1-10 kg/m2 increase in body mass index (BMI), or BMI 
≥25-30 kg/m2, all 19 reports showed significant direct associa-
tions (from 1.04 [1.02-1.05] to 2.24 [1.41-3.58]).
• For every 10-22 mm Hg increase in systolic blood pressure, or sys-
tolic blood pressure ≥160 mm Hg, most reports showed significant 
direct associations (from 1.14 [1.05-1.25] to 2.63 [1.83-3.78]).
• For diabetes mellitus (type unspecified), eight reports showed a direct 
but non-significant (from 1.02 to 1.49) and six reports showed signifi-
cant direct associations (from 1.17 [1.16-1.19] to 1.80 [1.30-2.60]).
Many of these conditions are present concomitantly. Also, obe-
sity and hypertension are commonly associated with sleep apnoea, 
which is another risk for incident AF.
Obesity has been associated with incident AF,182 but clinical trial 
data have a suggestion of an ‘obesity paradox’ whereby overweight 
AF patients tended to have improved outcomes; however, the rela-
tionship between obesity and outcomes from real-world observa-
tional cohorts are less clear.183–185 In a systematic review of trial and 
real-world evidence, there was suggestion of an obesity paradox in 
AF patients, particularly for all-cause and cardiovascular death out-
comes.184 An obesity paradox was also evident for stroke/systemic 
embolic event outcomes in the non-vitamin K antagonist oral anti-
coagulant (NOAC) trials, with a treatment effect favouring NOACs 
over warfarin for both efficacy and safety that was significant only 
for normal weight patients. Nonetheless, proactive management of 
obesity is part of the lifestyle advice for patients with AF.
On a population basis, hypertension is the most common aeti-
ological factor for AF, and contributes to its complications. Indeed, 
AF can be regarded as a manifestation of hypertension target organ 
damage. The optimal blood pressure targets in AF patients have 
been described, being 120-129/<80 mm Hg.186 Also, longer hyper-
tension duration is associated with the increased risk of ischaemic 
stroke; however, this long-term effect of hypertension duration can 
be attenuated by long-term strict SBP control throughout the entire 
duration of hypertension.187
Poor diabetes control is associated with incident AF. In the dia-
betic AF patient, longer disease duration is related to a higher risk 
of stroke/thromboembolism in AF, but not with a higher risk of an-
ticoagulant-related bleeding.188 These risks were similar for Type 
1 and Type 2 diabetes.189 Evidence of other target organ damage 
such as diabetic retinopathy increased risk, although it did not add 
to the predictive value of risk assessment using the CHA2DS2-VASc 
score.190 Indeed, the ATRIA study also confirmed that duration of 
diabetes is a more important predictor of ischaemic stroke than 
glycaemic control in patients who have diabetes and AF.191
Unsurprisingly SHD is a potent risk factor for incident AF, as 
well as its complications, such as stroke and HF.177,192 Systolic HF 
is one of the components of the simple C2HEST score (Chronic 
obstructive pulmonary disease and CAD [1 point each]; hyper-
tension [1 point]; elderly [age ≥75 years, 2 points]; systolic HF 
[2 points]; thyroid disease [hyperthyroidism, 1 point]) which has 
been derived and validated in a large cohort of AF patients.177 
This score could potentially be considered to target the high-risk 
patients that may be suited for more intense screening for inci-
dent AF, e.g. post-stroke where the C2HEST score was superior 
to the other scores such as the Framingham score.178 The risks of 
AF with associated valvular heart disease are well recognized, as 
recently discussed in an EHRA position document.193 In terms of 
HF, there is a link between AF complications and HF, whether HF 
with a reduced EF (HFrEF) or HF with a preserved EF (HFpEF).194 
In the CHA2DS2-VASc score, the ‘C’ component refers to recent 
decompensated HF, irrespective of the EF, or the presence of 
moderate-severe systolic dysfunction whether asymptomatic or 
not.7 Of note, the CHA2DS2-VASc score is predictive of stroke in 
HF, whether or not AF is present.195
3.4 | Patients who have undergone cardiac surgery
Patients who have undergone 
cardiac surgery Class References
Heart rhythm monitoring for 4-7 d 
is recommended for detection of 
post-operative AF
196–198
Patients with obesity, hypertension, 
diabetes, sleep apnoea, or structural 
heart disease Class References
Clinical risk factors should be 
assessed to help identify incident 
AF and its complications
176
Clinical risk scores may be useful to 
identify risk for incident AF
177–179
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Patients who have undergone 
cardiac surgery Class References
Patients with post-operative AF 
may undergo follow-up rhythm 
monitoring to assess for the 
presence of symptomatic and 
asymptomatic arrhythmias
196–199
Post-operative AF remains the most common complication fol-
lowing cardiac surgery and its incidence ranges between 20%-50% 
across numerous studies.196 This risk increases from isolated CABG 
surgery, to valvular surgery, and in turn to concomitant CABG/val-
vular surgery.
Risk factors for developing AF may be divided into procedural- and 
patient-related factors. Procedural-related risk factors include type of 
surgery, mitral valve surgery, use of intra-aortic balloon pump, longer 
cardiopulmonary bypass and aortic clamp times, and perioperative is-
sues such as inflammation, infection, fluid overload, inotropic use, atrial 
ischaemia, hypokalaemia, and hypomagnesaemia. Patient-related risk 
factors include advanced age, history of AF, history of HF, renal fail-
ure, hypertension, chronic obstructive pulmonary disease, post-opera-
tive withdrawal or absence of beta-blocker, or angiotensin-converting 
enzyme inhibitor (ACE inhibitor) therapy.197,200 Left atrial remodelling 
predisposes to post-cardiac surgery AF, with risk factors such as en-
larged left atrial size, diastolic dysfunction, LVH, obesity, obstructive 
sleep apnoea, and the CHADS2 and CHA2DS2-VASc score further pre-
disposing to post-operative AF.197,201,202
The majority of post-cardiac surgical AF occurs within the first 4 
post-operative days, and is most common on the 2nd post-operative 
day, while recurrences are most common on the 3rd post-operative 
day.197,203 In another study of CABG patients, 94% of post-opera-
tive AF occurred by the 7th post-operative day.198 Hence rhythm 
monitoring such as inpatient telemetry or ECG for post-operative AF 
should focus on this time frame.
While post-cardiac surgical AF likely occurs as a result of the in-
teraction between acute perioperative triggers and the underlying 
atrial and cardiac substrate, its occurrence identifies a subset of pa-
tients associated with long-term morbidity and mortality. In a study 
of patients who underwent CABG, post-operative AF conferred an 
eight-fold increased risk of future AF and doubled cardiovascular 
mortality on long-term follow-up.199 Follow-up rhythm monitoring, 
for example with ECG or Holter monitoring is advisable in this sub-
set of patients particularly in the setting of symptom development. 
There is emerging data on the use of implantable cardiac monitors 
for long-term monitoring of this subset of patients. While implant-
able cardiac monitors allow continuous long-term monitoring for 
arrhythmias and asymptomatic arrhythmias, the risk–benefit ratio 
is balanced by the arrhythmia detection rate beyond the immediate 
post-operative period and level of invasiveness of the monitoring de-
vice. Its routine use will depend on further results from prospective 
medium to long-term studies.
3.5 | Patients with cryptogenic stroke
Patients with cryptogenic 
stroke Class References
Patients should initially undergo 
brain diffusion-weighted MRI 
imaging for the diagnosis of 
cryptogenic stroke.
204,205
AF is more likely to be detected 
after cryptogenic stroke with 
more intense investigation with 
longer and more sophisticated 
monitoring.
205–207
Long-term ECG monitoring 
techniques, such as trans-
telephonic ECG monitoring 
or cardiac event recorders or 
ILR can increase yield of AF 
diagnosis after cryptogenic 
stroke in selected patients.
205,206
The use of an ILR should be 
considered for detecting AF in 
selected patients who are at 
higher risk of AF development, 
including the elderly, patients 
with cardiovascular risk factors 
or comorbidities.
80,207
F I G U R E  3   Investigations and 
associated risk factors useful to predict 
the development and progression 
of AF in HF patients. AF, atrial 
fibrillation; BNP, B-type natriuretic 
peptide; CRP, C-reactive protein; ECG, 
electrocardiogram; HF, heart failure; 
LA, left atrium; LGE, late gadolinium 
enhancement; LVH, left ventricular 
hypertrophy; MRI, magnetic resonance 
imaging. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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Patients with cryptogenic 
stroke Class References
TOE may lead to the 
reclassification of cryptogenic 
stroke because many cases 
are embolic and due to a 
cardiogenic source, mainly AF.
205,206
Cryptogenic stroke is defined as ischaemic stroke of undeter-
mined aetiology.208 The diagnosis of cryptogenic stroke is generally 
made by exclusion. Although cryptogenic stroke includes few po-
tential causes, such as paradoxical embolism through a patent fo-
ramen ovale, atrial septal aneurysm, and aortic arch atheroma, the 
majority of cases are thought to be caused by cardio-embolism due 
to undetected paroxysmal AF.205 For the diagnosis of cryptogenic 
stroke or a suspected transient ischaemic attack (TIA), patients 
should initially undergo brain imaging. Diffusion-weighted MRI is 
more recommended than any other MRI sequence or CT as brain 
imaging, except when contraindicated.204,205 Advances in cardiac 
imaging techniques such as transoesophageal echocardiography 
(TOE) have prompted the reassessment of cryptogenic stroke be-
cause most cases are thought to be embolic due to a cardiogenic 
source, mainly AF. Transoesophageal echocardiography can easily 
detect a thrombus of the left atrial appendage, particularly with 
contrast enhancement, which cannot be detected using conven-
tional transthoracic echocardiography. Transthoracic echocardi-
ography with contrast could be useful to detect a left ventricular 
thrombus (Figure 4).
The detection of permanent or persistent AF is relatively easy, 
whereas that of paroxysmal AF is more difficult. Current guide-
lines recommend the use of ECG monitoring among patients with 
ischaemic stroke including cryptogenic stroke and TIA for whom 
transient (paroxysmal) AF is suspected and no other causes of 
stroke are identified.205,206 First, 24-hours Holter ECG is per-
formed to detect the AF burden. If undetected, other long-term 
ECG monitoring techniques such as trans-telephonic ECG mon-
itoring or cardiac event recorders (a symptom event monitor or 
a ILR) may be attempted as alternative methods. A meta-analysis 
indicated that a longer duration of ECG monitoring is associated 
with an increased detection of new AF when examining monitor-
ing time as a continuous variable. Studies with monitoring lasting 
≤72 hours detected new AF in 5.1% of cases, whereas monitoring 
lasting ≥7 days detected AF in 15% of cases.209 The proportion of 
new diagnosis of AF was increased to 29.1% with 3-months ex-
tended monitoring. Recently, smartphone-based ECG recording 
systems have been developed and conferred acceptable sensi-
tivity and specificity of detecting AF191 (see Wearables/direct to 
consumer section).
The use of an ILR is indicated for detecting the presence of 
AF or arrhythmia burden that might cause ischaemic stroke in 
selected patients, for example those who are at higher risk of 
AF development including elderly, patients with cardiovascular 
risk factors or comorbidities. An ILR is a useful tool for detecting 
arrhythmias. In the CRYSTAL AF study, AF was newly detected 
in 8.9% of patients with an ILR by the 6th month compared with 
1.4% among those receiving conventional ambulatory ECG moni-
toring, increasing further to 12.4% by 12 months compared with 
2.0% in conventional monitoring.80 A similar outcome was ob-
served in the EMBRACE trial, in which AF was newly detected in 
16.1% of patients who received 30-day ILR compared with 3.2% 
who received ambulatory 24-hours monitoring.210 A systematic 
review indicated that AF was newly detected in nearly one-quar-
ter of patients with stroke or TIA by sequentially combining car-
diac monitoring methods: 7.7% in phase 1 (emergency room), 
5.1% in phase 2 (in-hospital), 10.7% in phase 3 (first ambulatory 
period), and 16.9% in phase 4 (second ambulatory period consist-
ing of trans-telephonic ECG monitoring, cardiac event recorders, 
and ILR), and 23.7% in the overall detection after all phases of se-
quential ECG monitoring.207 Thus, if we ‘look harder, look longer 
and look in more sophisticated ways’ we are more likely to detect 
AF. It is possible that if we use clinical risk stratification (e.g. the 
C2HEST score) to identify patients post-stroke at high risk of in-
cident AF, targeted intensive monitoring can be applied.211
3.6 | How to assess high risk of atrial fibrillation in 
professional athletes
Atrial fibrillation in 
athletes Class References
In athletes who 
participate long term 
in endurance exercises 
with symptoms of 
arrhythmia screening 
for AF is recommended
212
F I G U R E  4   Proceeding of evaluation for cryptogenic 
stroke. AF, atrial fibrillation; CT, computed tomography; ECG, 
electrocardiogram; ILR, implantable loop recorder; MRI, magnetic 
resonance imaging; TOE, transoesophageal echocardiography. 
[Colour figure can be viewed at wileyonlinelibrary.com]
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Atrial fibrillation in 
athletes Class References
Risk assessment for AF 
risk in athletes may 
include the duration and 
intensity of exercise as 
a potential modifiable 
risk factor
213,214
3.6.1 | Atrial fibrillation risk in athletes—general
Paroxysmal or persistent AF is common in athletes and may be au-
tonomically mediated or triggered by other supraventricular tachy-
cardias.215 AF is the primary arrhythmia observed in middle-aged 
athletes.216 AF in athletes tends to be paroxysmal, vagally mediated, 
and highly symptomatic.213 The mechanism of increased AF risk at 
either end of the physical activity spectrum likely includes auto-
nomic, structural, inflammatory, and fibrotic changes to the heart. 
For example, increased vagal tone, which is often observed in the 
endurance athlete, has been shown to result in a short atrial refrac-
tory period, and thus initiates AF.217
3.6.2 | Atrial fibrillation risk in athletes—
exercise paradox
Recent studies have observed a U-shaped risk relationship of 
physical activity to AF. At one end of the spectrum, a large ob-
servational study218,219 of people showed that those at the low-
est levels of physical fitness had a 5-fold increased risk of AF.220 
Increasing the physical activity of sedentary patients could help 
reduce the risk or burden of AF. Long-term endurance training, as 
well as a sedentary lifestyle,221 increase chronic systemic inflam-
mation, which in turn could also facilitate AF.106 For example, one 
randomized study demonstrated that just 12 weeks of moderate-
intensity physical activity decreased the AF burden by 41%.222 Of 
the physically inactive with AF, the obese might benefit the most 
from moderate levels of physical activity.220 In contrast, a meta-
analysis of 655 endurance athletes also demonstrated a five-fold 
increased risk of AF.212 Of these studies, increased AF risk was 
generally only observed with the highest levels of physical activity 
that was maintained over a prolonged period of time.213,214 One 
uniform explanation for the exercise paradox is that both long-
term endurance training and a sedentary lifestyle increase chronic 
systemic inflammation.
3.6.3 | Atrial fibrillation risk in athletes—structural 
cardiac changes
Most studies have shown structural changes in endurance ath-
letes, which have resulted in the term athlete’s heart. These 
changes include dilatation of all four heart chambers, increase in 
left ventricular mass, and mild right ventricular hypertrophy.223 
Studies show that moderate physical activity might reduce inflam-
matory markers.224–226 Extreme levels of exercise are a known 
cause of cardiac fibrosis, particularly in hinge point locations of 
the heart, such as the right ventricle; however, the significance 
of MRI-detected fibrosis remains controversial.227 Athletes who 
experience higher levels of fibrosis also have higher levels of coro-
nary calcium.228 In turn, fibrosis is a well-established risk factor of 
AF.163 In one study, the fibrotic changes caused by vigorous exer-
cise were reversed after an 8-week period of physical activity ces-
sation.229 Among young elite athletes, age, years of competition, 
and echocardiographically measured parameters, including left 
atrial anterior–posterior diameter and atrial strain, were associ-
ated with higher AF risk.230,231 Although increasing physical ac-
tivity might reduce AF in sedentary patients, decreasing physical 
activity levels in elite endurance athletes may also reduce AF.215 
Currently, the role of deconditioning to lower AF risk in elite ath-
letes for primary or secondary prevention of arrhythmia requires 
prospective evaluation.
3.7 | Patients with inherited rhythm disease (long 
QT syndrome/short QT syndrome/catecholaminergic 
polymorphic ventricular tachyarrhythmia/Brugada 
syndrome)
Patients with inherited 
rhythm disease Class References
Patients with certain 
inherited arrhythmia 
syndromes are at higher 
risk for AF and benefit 
from symptom-driven and 
periodic surveillance
123
Evaluation should include 
non-invasive symptom-
driven surveillance 
for patients at risk for 
AF and periodic non-
invasive surveillance for 
asymptomatic patients
232–234
EPS to determine atrial AF 
substrate or susceptibility 
is not useful.
123
Some patients with primary electrical sudden death syndromes 
have an increased AF association, including Brugada Syndrome, 
LQTS, SQT, and catecholaminergic polymorphic ventricular tachy-
cardia (CPVT). These patients are at risk for arrhythmia symptoms 
from AF and are vulnerable to AF consequences such as pro-ar-
rhythmia and inappropriate ICD shocks.
Brugada Syndrome is characterized by ST-segment elevation in 
the precordial ECG leads and increased risk of SCD due to VF.235 
Brugada Syndrome is associated with a higher incidence of SVTs, and 
AF is the most common SVT in these patients.236,237 AF susceptibility 
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has been described with patients harbouring mutations in SCN5A, 
CACNA1C and patients without an identified genotype,234,238 sug-
gesting a lack of genetic AF specific risk but AF may be more prev-
alent with more advanced disease.239,240 Importantly, AF events 
can be pro-arrhythmic for Brugada Syndrome patients123,241 and 
contribute to the high inappropriate ICD shock rates for Brugada 
Syndrome patients.241
Long QT syndrome is a genetically heterogeneous syndrome as-
sociated with mutations in 17 different genes with some unique phe-
notypic characteristics based on genotype and electrically results 
in prolonged repolarization and risk for fatal ventricular arrhythmia 
torsade de pointes. While generally, prolonged repolarization in-
hibits AF initiation and this is the mechanism for Vaughn–Williams 
Class III anti-arrhythmic drugs, rare patients with LQTS have also 
been noted to have AF.242,243 This has been limited to single case 
reports and unverified, 1.7% of patients in a LQTS cohort, which is 
a higher prevalence than the general population.133,244 Not surpris-
ingly, some genes associated with AF in LQTS have overlap with fa-
milial AF: LQT1 (KCNQ1), LQT2 (KCNH2), LQT3 (SCN5a), and LQT7 
(KCNJ2). However, for potassium channels, in LQTS the genetic de-
fect results in ‘loss of function’ in contrast to a ‘gain of function’ in 
familial AF.245,246 It is less clear how prolonged repolarization results 
in AF susceptibility but it may involve similar mechanisms to torsade 
de pointes247 or perhaps dispersion of repolarization and induction 
of early after depolarizations.248,249
From an electrical substrate standpoint, it is easier to understand 
why SQTS and CPVT are associated with AF. Short QT syndrome is 
a rare disorder caused by a gain of function of potassium channels 
encoded by KCNQ1, KCNH2, and KCNJ2, causing a shortening of 
the action potential and manifests in the atrium by a decreased atrial 
refractory period and electrical substrate for AF.250–252 CPVT is an 
autosomal dominant disorder associated with polymorphic VT and bi-
directional VT due to cellular calcium overload caused by mutations in 
calcium handling genes.253–255 A reciprocal condition can exist in the 
atria of patients with CPVT with AF susceptibility and has been shown 
to be more prevalent in patients with more dysfunctional ryanodine 
receptor2 channels.256 It is also unclear how clinically significant AF 
is for CPVT patients. However, the failure to recognize and treat AF 
can result in inappropriate shocks, pro-arrhythmia, and death.232,233
These issues highlight the need for AF recognition, ICD program-
ming to reduce the risk of inappropriate shocks, and preventative 
treatment. Because of the small cohort sizes and lack of systematic 
studies, it is difficult to prospectively estimate AF risk. Invasive EP 
studies evaluating atrial refractory periods, conduction time, and AF 
inducibility have been inconclusive236,237 and either not systemat-
ically evaluated in large populations or are contraindicated (LQTS 
and CPVT).123 We support vigilant non-invasive surveillance in 
these conditions. For patients with ICD, close follow-up is needed 
to decipher and to adjudicate if atrial arrhythmias are present and 
proactively increase the rate cut-off for VF detection and turn SVT 
discriminators on, if available. Patients without ICD, but suggestive 
symptoms, should undergo ambulatory monitoring and asymp-
tomatic patients should have surveillance monitoring done every 
1-2 years. Treatment is not the focus of this article, but it should 
be recognized that many AADs can worsen the electrical substrate 
for inherited arrhythmia patients (i.e. LQTS, Brugada Syndrome) and 
care should be taken when choosing antiarrhythmic drugs.
4  | HOW TO A SSESS RISK FOR ADVERSE 
OUTCOMES IN PATIENTS WITH ATRIAL 
FIBRILL ATION
4.1 | Risk assessment for stroke/transient ischaemic 
attack/cognitive decline
Risk assessment for stroke/TIA/
Cognitive decline Class References
A risk factor-based approach is 
recommended for stroke risk 
assessment in patients with AF
8,257
Cognitive assessment should be 
performed in AF patients where 
there is suspicion of cognitive 
impairment.
258,259
Assessment of cognitive function 
may be multifaceted, and cognitive 
impairment screening by available 
tools is just one component.
258
Risk reduction of cognitive 
dysfunction and its comorbidities 
in AF may include risk assessment 
for vascular disease and/or 
Alzheimer’s disease.
258,260
General health measures may 
reduce the concomitant risks of AF 
and stroke, with a putative benefit 
on cognitive function.
1,2
Patients with AF have increased mortality and morbidity com-
pared with non-AF patients and may experience significant adverse 
events. Stroke and thrombo-embolic events are well known compli-
cations that can be avoided by oral anticoagulation. Since the risk of 
individual patient differs significantly, an individual risk assessment 
is necessary. Several stroke risk scores, including ABC-stroke (age, 
biomarker, clinical history), ATRIA (Anticoagulation and Risk Factors 
in Atrial Fibrillation), GARFIELD (Global Anticoagulant Registry in the 
FIELD), and Qstroke have been proposed as support tools for the de-
cision on oral anticoagulation.261–264 However, the one currently most 
widely applied and recommended by international guidelines is the 
CHA2DS2-VASc risk scheme. According to CHA2DS2-VASc, patients 
with score of ≥1 in a male or ≥2 in a female should be considered for 
stroke prevention strategies.265–268 Nevertheless, it has to be kept 
in mind that no stroke risk scheme has perfect predictive accuracy.
Another major adverse effect of AF is impairment of cognitive 
function.258,259 Multiple risk factors for dementia have been iden-
tified in the general population, including modifiable and non-mod-
ifiable ones.269 Apart from these AF-non-specific risk factors, AF 
may lead to cognitive impairment by multiple mechanisms. These 
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include apparent stroke, silent stroke but also other mechanisms 
that are independent of thromboembolism.270 A detailed descrip-
tion of the association between AF and cognitive impairment and 
possible preventive mechanisms has been provided recently in an 
expert consensus document.258 In terms of prevention of cognitive 
impairment in AF patients, there is evidence that early and effec-
tive use of oral anticoagulation in patients with stroke risk factors 
reduces the rate of cognitive decline and currently, this represents 
the most important preventive strategy. Consequently, the main risk 
assessment for cognitive impairment in AF patients is the assess-
ment of stroke risk factors, preferably by use of the CHA2DS2-VASc 
risk scheme that can guide the decision on oral anticoagulation. 
When cognitive impairment is suspected, brief screening tools 
such as General Practitioner Assessment of Cognition (GPCOG), 
Mini Mental State Examination (MMSE) and Montreal Cognitive 
Assessment (MOCA), and Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE) may be applicable.258 In addition, 
more comprehensive assessments may be done after appropriate 
referral to a psychiatrist, geriatrician, or neurologist.258
4.2 | Risk assessment for stroke/transient ischaemic 
attack status post-left atrial appendage occlusion/
ligation
Risk assessment for stroke/TIA after 
LAA occlusion/ligation Class References
TOE after 6 weeks and if necessary 
after 1 year is useful for detecting 
peri-device residual flow, incomplete 
appendage ligation, or device-related 
thrombus to identify patients at 
higher risk of stroke
271,272
Clinical features such as previous 
TIA/stroke, persistent AF, low 
LVEF, vascular disease, and early 
discontinuation of anticoagulation 
may be helpful to guide decisions 
regarding imaging for device related 
thrombus
273,274
Multi-detector CT and cardiac CT 
angiography have been found to be 
equivalent to TOE to detect peri-
device flow
275,276
After surgical occlusion or exclusion 
of the left atrial appendage, imaging 
may be useful to look for a residual 
appendage and its function or a 
residual leak after ligation to guide 
decisions regarding anticoagulation
277–279
Left atrial appendage (LAA) occlusion/ligation using one of sev-
eral devices or surgical techniques has been developed as an al-
ternative to anticoagulation in high-risk patients with non-valvular 
AF.280–282 The maximum experience has been with the Watchman 
device (Boston Scientific), which has been found to be non-infe-
rior to warfarin in patients who are still candidates for short-term 
warfarin treatment.283–285 Results of comparison between LAA oc-
clusion/ligation and NOACs are awaited. Current guidelines recom-
mend use of LAA occlusion as a possible strategy in patients having 
contraindications to long-term anticoagulation.279
The residual risk of stroke/TIA following LAA occlusion/ligation 
can be related to procedural or patient related risk factors. Among 
the procedure related factors, peri-device leak, and device-related 
thrombus are important factors for thrombo-embolic events in short 
and medium term after the procedure. Stroke risk is significantly el-
evated in patients in whom LAA ligation fails after surgical286 or per-
cutaneous approaches.287
Post-procedure surveillance is therefore important to assess 
long-term risk of stroke and need for continued anticoagulation. 
These may be detected on TOE immediately or after few weeks/
months.271,272 Multidetector CT and cardiac CT angiography have 
been compared with TOE and found to be an effective alternative 
technique to detect peri-device flow.275,276 Device-related throm-
bus is seen in 3%-7% of patients after LAA closure, and leads to a 
3-4 fold higher risk of stroke.273,274 Factors predicting device-re-
lated thrombus are previous TIA/stroke, persistent AF, low LVEF, 
vascular disease, and early discontinuation of anticoagulation.273,274
If surgical LAA ligation fails or is incomplete, stroke rates are 
significantly increased. Similarly, with percutaneous closure devices, 
residual LAA leaks were associated with increased risk of thrombo-
embolism in excess of that associated with baseline risk factors or 
echocardiogram findings.286
4.3 | Risk for heart failure incidence and progression
Risk for heart failure incidence and 
prognosis Class References
Screening for AF in patients with 
HF should be performed because 
of the increased risk of adverse 
cardiovascular outcomes in 
combination more than the risk 
conveyed by either disease state alone.
288,289
Interval use of echocardiography 
and arrhythmia directed monitoring 
for development of AF-induced 
cardiomyopathy and risk assessment 
over time should be part of standard 
follow-up for patients with AF.
290,291
Atrial fibrillation and HF are conditions that coexist in many pa-
tients, and sometimes it will be difficult to establish if HF was the 
cause of AF or AF caused HF (tachycardia-induced cardiomyopa-
thy).288,292 In the Framingham study, 41% of patients with AF and 
HF developed HF first, 38% developed AF first, and in the remain-
ing 21%, AF and HF occurred at the same time.289 AF is associated 
with a three-fold increased risk of incident HF.293 In trials of patients 
with chronic systolic heart failure, the prevalence of AF was 4% in 
patients with Class I symptoms, 10%-27% in patients with Class 
II-III symptoms, and 50% for those with Class IV HF symptoms.291 
Additionally, aging and the structural and neurohormonal changes in 
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HF make the development and progression of AF much more likely. 
The risks of developing an AF-induced cardiomyopathy appear to 
be related to the ventricular rate during AF and the duration of AF. 
However, the precise incidence of tachycardia-induced cardiomyop-
athy with AF, in patients with and without SHD is unknown.
The mechanisms and pathophysiology of AF and HF share several 
risk factors and common pathophysiologic processes. Hypertension, 
smoking, obesity, diabetes, renal impairment, sleep apnoea, and CAD 
are all associated with an increased risk of developing both HF and 
AF, and each condition increases morbidity and mortality when as-
sociated with the other. All types of HF (HFpEF or HFrEF) are asso-
ciated with an increase prevalence of AF.294,295 There are no studies 
examining the role of monitoring to detect AF in asymptomatic pa-
tients with HF or the management of AF if detected. For patients 
with cardiac implantable electronic devices, remote monitoring is 
a tool for determining AF burden and is part of routine device fol-
low-up. In patients with HF, the risk of AF is increased by several 
mechanisms, remodelling of atrial structure and increased fibrosis, 
ectopy promoted by atrial stretch, increased spontaneous firing in 
the pulmonary veins and alterations in calcium current handling in 
the atrial muscle and sarcoplasmic reticulum calcium content.290
The loss of atrial systole in AF impairs LV filling and can result in left 
ventricular dilatation, decrease in myocardial blood flow and increase in LV 
wall stress and end-diastolic pressure. Atrial fibrillation can decrease car-
diac output by 25% particularly in patients with diastolic dysfunction. The 
mechanisms for reduction in cardiac output include loss of atrial contribu-
tion to ventricular filling, increased mitral regurgitation and decreased left 
ventricular filling time. The irregular and rapid ventricular contraction in 
AF can lead to LV dysfunction in an unknown percentage of patients and 
in some patients a tachycardia-induced cardiomyopathy results.291 The 
irregular ventricular response also compromises ventricular performance 
through changes in calcium handling and reduced expression of Serca and 
phospholamban phosphorylation. Management can vary widely accord-
ing to presentation and should be individualized since treatments shown 
to be effective in one or other condition alone, may give rise to safety 
or efficacy issues in an individual patient. Several recent trials have sug-
gested a preferential role for primary catheter ablation of AF in select AF 
patients with HF compared to medical therapy alone.296–298 Treatment of 
AF by either rate or rhythm control may reverse the cardiomyopathy and 
improve clinical HF substantially in selected patients.
4.4 | Risk for death in atrial fibrillation patients
Risk for death in AF patients 
(including risk for SCD) Class References
Clinical characteristics of the patient 
including presence of advanced age, 
cognitive dysfunction or dementia, 
diabetes mellitus, hypertension, 
prior stroke, vascular disease, and 
HF should be used as important 
risk markers of higher mortality in 
patients with AF.
299,300
Atrial fibrillation is associated with 1.5- to 2-fold higher risk of 
all-cause mortality which may result from stroke, HF, or SCD.279 Of 
the mortality associated with AF, only 1 in 10 deaths are stroke, and 
>7 out of 10 are cardiovascular.301 A multipronged strategy incorpo-
rating stroke prevention, better symptom control, and cardiovascular 
risk optimization is associated with improved outcomes, including a 
reduction in mortality.3,4 Females with AF have slightly higher mor-
tality compared to male patients. Ethnic or racial differences exist 
in mortality risk, with one study showing highest risk in African 
Americans among all racial/ethnic groups.302 Also, presence of co-
morbidities increases the risk compared with ‘lone’ AF. Advanced age, 
renal failure, pulmonary disease, and HF have been found to be most 
important risk factors for higher mortality in AF (Figure 5).299,300
Numerous risk scores have been designed to assess the mortality 
risk in AF. The CHA2DS2-VASc score was designed to assess stroke 
risk, but given it is a cluster of common risk factors for cardiovas-
cular mortality also predicts mortality risk.303 More complex clini-
cal risk scores designed to predict mortality, such as an integrated 
GARFIELD-AF risk tool, statistically improves mortality prediction, 
being superior to the CHA2DS2-VASc score.
304 All clinical risk scores 
only have modest predictive value (c-indexes 0.6-0.7) but can always 
be statistically improved by the inclusion of cardiac biomarkers, 
such as NT-proBNP and hs-TnT. Both biomarkers (and others) have 
been found to be independently associated with increased midterm 
mortality in AF patients presenting to emergency room.305 Indeed, 
risk scores incorporating biomarkers have been proposed, such as 
the ABC-death risk score, which utilizes age, biomarkers, and clin-
ical history. The ABC-death score achieved a c-index of 0.74 (95% 
confidence interval [CI] 0.72-0.76), while the CHA2DS2-VASc score 
achieved a c-index of 0.58 (95% CI 0.56-0.61).306 However, the clini-
cal usefulness of any risk-prediction score for mortality has not been 
established, and further validation studies are needed. Indeed, many 
risk factors or biomarkers are based on measurements done at base-
line, and follow-up events occur many years later. Cardiovascular risk 
is not static but changing with increasing age and incident risk fac-
tor(s), thus repeat risk re-assessment is more appropriate given that a 
change in risk scores is more highly predictive of adverse outcomes.
Importantly, many biomarkers are non-specific, more likely re-
flecting a patient with significant comorbidities and significant 
F I G U R E  5   Mortality risk in patients with atrial fibrillation. 
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underlying heart disease, and are predictive of various endpoints 
apart from death, including stroke, heart failure, etc.307,308 Indeed, 
biomarker-based scores like ABC-death were derived from a highly 
selected clinical trial cohort which was anticoagulated, and values 
were determined at study entry (baseline). Many biomarkers also 
have a diurnal variation and inter/intra laboratory variability and are 
predictive of non-cardiovascular outcomes. Real-world studies in-
vestigating the usefulness of sequential addition of biomarkers have 
shown limited value over conventional clinical risk scores.10,309,310 
Thus, statistically significant improved prediction should not be con-
fused with clinically improved risk prediction. A balance is therefore 
needed between (statistically) improved risk prediction and simplic-
ity or practicality for everyday clinical use in busy clinical settings. 
In summary, any novel biomarker (or biomarker-based scores) would 
need to be validated in large non-anticoagulated cohorts. This is the 
starting point of risk stratification with the newly diagnosed AF pa-
tient in any patient care pathway, and be simple, practical and ade-
quately validated to account for the dynamic nature of risk factors 
and changes in drug therapies (including the use of antithrombotic 
drugs) over time.
Stroke resulting from AF has significant medium-term mortality, 
which can be as high as 30.5% at 1 year.311 An 8-point GPS-GF score 
utilizing variables including Glasgow Coma Scale, pneumonia, mid-
line shift on brain images, blood glucose, and female sex has been 
developed and was found useful to predict 30-day mortality in pa-
tients with AF-related stroke.312
Spontaneous AF is associated with an increased risk of SCD in 
patients with Wolff–Parkinson–White (WPW) syndrome, HCM, and 
channelopathies such as Brugada syndrome.279 Several recent studies 
on HF and LVH and those on the general population have reported 
that AF is linked to an increased risk of SCD.313–315 Mechanisms for 
SCD due to AF are well understood for WPW syndrome or HCM, but 
are unclear regarding other cardiac disorders. A meta-analysis demon-
strated a significant association between AF and SCD in the general 
population as well as in patients with CAD, congestive HF, HCM, 
Brugada syndrome, and implanted rhythm devices.316 In a nationwide 
cohort study from Taiwan, 352 656 patients were identified. Among 
AF patients, age ≥75 years, congestive heart failure, hypertension, 
diabetes mellitus, previous stroke/TIA, vascular diseases, chronic 
kidney disease, and chronic obstructive pulmonary disease were im-
portant risk factors for SCD or ventricular arrhythmias.317 A recent 
study suggested that optimal pharmacological treatment, in addition 
to anticoagulant therapy, can reduce SCD rates in patients with AF.318 
Since pharmacological rhythm control has so far been relatively inef-
fective in preventing SCD in AF patients with low LVEF,319 catheter 
ablation may be more appropriate for improving prognosis in patients 
with AF.297 To assess the risk of SCD in patients with AF, recogniz-
ing the presence of CAD, HF, LVH/HCM, pre-excitation, Brugada 
syndrome, and implanted rhythm devices is crucial. Examinations in-
cluding 12-lead ECG, echocardiography, and other imaging modalities 
such as cardiac MRI are useful for detecting various cardiac disorders. 
Electrophysiological testing is useful for identifying risks in patients 
with WPW syndrome and paroxysmal AF.
4.5 | Risk of adverse outcomes in patients treated 
with catheter ablation
Radiofrequency (RF) ablation has emerged as a main therapeutic 
option for treatment of AF patients since 1998 after the observation 
that AF mostly initiates from arrhythmogenic triggers in muscular 
sleeves in the pulmonary veins.327 There is abundant evidence that 
AF ablation is an effective method for AF suppression leading to sig-
nificant reduction of AF episodes and burden accompanied by sub-
stantial improvement in symptoms and quality of life if performed in 
symptomatic patients. For this reason, AF ablation is mainly recom-
mended by current guidelines as a method for symptom improve-
ment in symptomatic AF patients.279
4.5.1 | Post-ablation atrial fibrillation recurrence
Post-ablation AF recurrence is one of the most important and fre-
quent adverse outcomes, which occurs in 30%-50% of cases.328,329 
In fact, although the acute success rate of AF catheter ablation 
seems high, achieving a durable treatment efficacy has remained 
a main challenge.279,329 Different factors including female gender, 
older age, traditional cardiac risk factors, left ventricular dysfunc-
tion, increased epicardial adipose tissue, myocardial fibrosis, and 
atrial enlargement have been proposed as possible predictors of 
post-ablation AF recurrence.330–332 Moreover, diverse AF recur-
rence risk-prediction scores, including APPLE, ALARMEc, ATLAS, 
BASE-AF2, CAAP-AF, DR-FLASH, and MB-LATER have been in-
troduced; however, their integration into the daily clinical practice 
needs further support by healthcare systems.333–342
4.5.2 | Other adverse outcomes
Apart from AF recurrence, according to the available real-world 
data, around 5%-15% of patients undergoing AF catheter ablation 
experience complications, mainly during the index hospitalization 
Risk of adverse outcomes in 
patients treated with catheter 
ablation Class References
Patients that undergo an AF 
ablation should be monitored 
closely in the first 30 days after 
the procedure due to a higher risk 
of neurological, gastrointestinal, 
cardiovascular, vascular and 
peripheral complications
320–325
Wolff–Parkinson–White syndrome 
patients following radiofrequency 
ablation may benefit from 
additional follow-up due to 
a persistent elevated risk of 
developing AF compared to the 
general population
296,326
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and early in the post-procedure course.320–325 A variety of compli-
cations, including neurological, gastrointestinal, cardiovascular, vas-
cular and peripheral, as well as pulmonary complications have been 
reported to occur after ablation procedures.320–325,343–347 Although 
different modifiable factors such as metabolic syndrome, hyperten-
sion, alcohol consumption, sleep apnoea, and obesity have been 
proposed to be related with arrhythmia-free survival after catheter 
ablation,348–351 their impact on the ablation adverse outcomes is not 
clear yet, and requires further investigations.
Mortality and morbidity
The impact of the ablation on hard clinical endpoints is much less 
evident. Previous findings from observational studies indicated 
a positive effect of the procedure on mortality and morbidity.352 
These, however, were not confirmed in the recent large rand-
omized Catheter Ablation vs Antiarrhythmic Drug Therapy for 
Atrial Fibrillation Trial (CABANA) that had as primary endpoint a 
composite of death, disabling stroke, serious bleeding, or cardiac 
arrest.296 In contrast, positive effects on hard clinical endpoints 
including mortality have been reported in patients with HF. In the 
CASTLE-AF trial, patients with impaired LVEF <35% and previous 
ICD implantation who were treated with ablation therapy had a 
lower rate of death from any cause or hospitalization for worsen-
ing HF compared to patients undergoing medical treatment.297
Stroke
Regarding the impact of AF ablation on stroke and in particular the 
validity of stroke risk schemes for stroke risk stratification after 
ablation, observational data suggest a reduced stroke risk after AF 
ablation and a possibly safe termination of anticoagulation, at least 
in selected patients.353,354 Conclusive evidence is expected from on-
going randomized trials as the Optimal Anticoagulation for Higher 
Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial 
(OCEAN) (NCT02168829) and the Prevention of Silent Cerebral 
Thromboembolism by Oral Anticoagulation with Dabigatran After 
Pulmonary Vein Isolation for Atrial Fibrillation (ODIn-AF) trial 
(NCT02067182). Until now, one randomized trial showed that abla-
tion therapy for AF in patients with impaired LVEF was associated 
with significantly lower rate of death from any cause and worsening 
HF.274 Subgroup recommendations may change after the completion 
of trials studying the effect of ablation on stroke and the need for 
anticoagulation. Particularly in HF patients, it remains to be seen in 
which subgroups of patients the data indicating mortality reduction 
after AF ablation are applicable.
4.5.3 | Catheter ablation in Wolff–Parkinson–
White patients
Careful attention must be given in WPW patients who underwent 
RF ablation, as it was demonstrated that they had an increased risk 
of AF at follow-up when compared to general population, though an 
increased risk of death was not reported.297,326
4.6 | Risk of adverse outcomes in patients treated 
with surgical Maze
The surgical Cox–Maze operation was introduced in 1987 to treat 
patients with refractory AF.355 This surgical approach carries more 
risk of complications than the catheter ablation procedure, and is 
suitable for selected patients only. In this setting, we can observe 
three different case-scenarios.
4.6.1 | Atrial fibrillation surgery
A simplification of the Cox–Maze procedure was proposed by 
replacing the ‘cut and sew’ lesions by different ablation devices 
and minimally invasive access.356 In the recent years, bipolar RF 
clamping devices guided on a beating heart, by thoracoscopic 
epicardial approaches have been introduced.277,357 This evolu-
tion has allowed the implementation of this surgery for stand-
alone persistent and long-standing persistent AF ablation, after 
an ineffective antiarrhythmic drug treatment or a previous en-
docardial ablation failure with a IIa (Level of Evidence B) indica-
tion.278 On another hand, this invasive approach carries some 
potential risks that need to be anticipated and discussed. Ideally, 
this step should involve an arrhythmia team in order to discuss 
the risk–benefit balance of the procedure on a case by case 
basis.358
4.6.2 | Surgical Maze in patients with concomitant 
heart surgery
An AF surgical ablation procedure is reasonable for selected 
patients with AF undergoing cardiac surgery for other indica-
tions.279 In patients that may receive a concomitant Maze pro-
cedure, a shared decision-making strategy should be used with 
an AF heart team to make the best decision available for the pa-
tient and their heart condition.358 Mortality or major morbidity 
was not affected by concomitant AF surgery (adjusted odds ratio 
[OR] 1.00; 95% CI 0.83-1.20), but pacemaker implantation was 
more frequent (adjusted OR 1.26; 95% CI 1.07-1.49).359 Stiff LA 
syndrome was also reported after surgical Maze procedure, pre-
senting with dyspnoea, pulmonary hypertension, and elevated 
left ventricular end-diastolic pressure attributed to reduced LA 
compliance.360
Predictors of AF recurrence after surgery include left atrial dil-
atation, older age, over 10-year history of AF, and non-paroxysmal 
AF.361–365
4.6.3 | Stand-alone surgical Maze
A stand-alone AF surgical ablation procedure may be reason-
able for selected patients with highly symptomatic AF not 
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well managed with other approaches (e.g. after a failed cath-
eter ablation, longstanding AF, dilated left atrium).366 After 
Cox–Maze IV stand-alone procedure, overall operatory mor-
tality was 1%-1.8%, overall complication rate was 10%, 8% 
required pacemaker placement, and 12-month freedom from 
atrial tachyarrhythmias was 89% (78% without antiarrhythmic 
drugs).367,368
4.6.4 | Left atrial appendage exclusion or removal 
during surgical Maze
The prospective randomized trial comparing the efficacy and safety 
of LAA exclusion or removal with surgical Maze procedure is lack-
ing. However, epicardial LAA Atriclip occlusion showed a high rate 
of complete left atrial appendage occlusion and reduces the inci-
dence of stroke in patients with AF undergoing cardiac surgery.282 
After surgical occlusion or exclusion of the LAA, it is recommended 
to continue anticoagulation in at-risk patients with AF for stroke 
prevention.279 If surgical LAA ligation fails or is incomplete, stroke 
rates are significantly increased compared to patients with complete 
closure.286
5  | HOW TO A SSESS RISK FOR 
VENTRICUL AR TACHYARRHY THMIA IN 
SPECIFIC POPUL ATIONS
5.1 | Patients with ischaemic heart disease
Ventricular tachyarrhythmia/ventricular fibrillation events are 
closely related to the risk of SCD in patients with ICM. For this 
reason, the risk of VT/VF is commonly used as a surrogate for 
the risk of SCD. In addition, in ischaemic cardiomyopathy (ICM), 
myocardial ischaemia is the most common trigger for VF and 
SCD.
For primary prevention, our current approach to SCD risk 
stratification relies mainly on the evaluation of LVEF: values 
below 30%-35% allow the identification of ICD candidates, who 
are at highest relative risk of SCD. On the other hand, patients 
with a LVEF >35% account for the highest absolute number of 
SCDs.369 For this reason, many researchers emphasize that EF is 
an inadequate marker for detecting patients who are at high risk 
for SCD despite having a normal or sub-normal EF. It seems also 
to have very limited value to identify amongst patients with a 
low LVEF those who will benefit the most from an ICD. In other 
words, many patients with EF ≤35% are unnecessarily implanted 
with an ICD for primary prevention, while some others, having a 
EF >35% and a high risk of VT/VF, are not protected. In this set-
ting, new markers are needed to optimize screening and patient 
selection for ICD implantation. For secondary prevention, SCD 
risk is significantly higher, and risk stratification is certainly more 
standardized.61,74
5.1.1 | Secondary prevention of ventricular 
tachyarrhythmia/ventricular fibrillation in patients 
with ICM
Secondary prevention of VT/VF in 
patients with ICM Class References
ICM substrate and ischaemic triggers 
for VT/VF must be evaluated 
when appropriate (coronary 
angiogram, functional ischaemic 
evaluation by nuclear scan, stress-
echocardiography, or MRI)
54,70,71
Cardiac MRI with a LGE can be 
considered in order to evaluate 
arrhythmogenic substrate including 
myocardial scarring to include in risk 
assessment, and guide a possible 
VT ablation procedure. This 
investigation should be preferably 
performed before ICD implantation 
to avoid artefacts due to the 
presence of an implanted device
370
For more than 20 years, patients with a history of sustained VT/VF 
have been recognized to be at high risk of recurrence.371 Nowadays, 
these patients are given a Class I (Level of Evidence A) indication for 
ICD implantation.70 For this reason, the practical usefulness of VT/
VF recurrence risk assessment is questionable, as additional testing is 
likely not going to influence decision pathways (i.e. catheter ablation 
or antiarrhythmic drug therapy as an alternative to ICD implantation), 
and patient outcomes in a secondary prevention setting.
5.1.2 | Primary prevention of ventricular 
tachyarrhythmia/ventricular fibrillation in patients 
with ICM and a left ventricular ejection fraction ≤35%
Patients presenting with ICM, in NYHA Class II-III, with EF ≤35% 
after 3 months of optimized heart failure pharmacological treat-
ment, are given a Class I/A indication for ICD implantation for the 
Primary prevention of VT/VF in 
patients with ICM and LVEF ≤35% Class References
ICM substrate and ischaemic triggers 
for VT/VF must be evaluated 
when appropriate (coronary 
angiogram, functional ischaemic 
evaluation by nuclear scan, stress-
echocardiography or MRI)
54,70,71
Cardiac MRI with a LGE can be 
considered in order to evaluate 
arrhythmogenic substrate including 
myocardial scarring to include 
in risk assessment and guide a 
possible VT ablation procedure. This 
investigation should be preferably 
performed before ICD implantation 
to avoid artefacts due to the 
presence of an implanted device
370
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primary prevention of SCD.70 Nonetheless, it is widely recognized 
that only a small subgroup of these patients will present with VT/
VF during follow-up, and consequently will benefit from the de-
vice. A better risk stratification of these patients would be crucial 
to help identify those who would indeed benefit from an ICD. Most 
of the numerous investigations assessed in this setting, like pro-
grammed ventricular stimulation (PVS), heart rate variability (HRV), 
late ventricular potentials (LVP), baroreflex sensitivity, QT interval 
dispersion, T-wave alternans, and heart rate turbulence have been 
largely abandoned because none of them have influenced routine 
clinical practice.46,73,372,373 However, some of these explorations, 
like T-wave alternans, have shown some value for SCD prediction in 
ICM patients.42 It is still uncertain whether biochemical markers as 
B-type natriuretic peptide and N-terminal pro-BNP will prove useful 
in assessing risk for VT/VF. Cardiac MRI with LGE should also help 
to improve VT/VF and SCD risk stratification by analysing cardiac 
structure and myocardial scarring.376 Finally, a recent randomized 
trial suggests that assessment for hibernating myocardium per-
formed routinely is of no use to decrease the risk of SCD.68
5.1.3 | Primary prevention of ventricular 
tachyarrhythmia/ventricular fibrillation in patients 
with ICM and left ventricular ejection fraction >35%
This group of patients should be the priority for VT/VF risk as-
sessment: in absolute numbers, it represents by far the highest num-
ber of those at risk of VT/VF and SCD.369 In addition, these patients 
are currently non-protected, as they are not targeted for ICD implan-
tation in guidelines, due to their LVEF value.70 In this setting, MRI 
with LGE could be an option to better understand the diagnosis, pre-
diction, and treatment of VT/VF.370 This investigation could possibly 
help improve VT/VF and SCD risk stratification by analysing cardiac 
structure and myocardial scarring, particularly when EF is relatively 
preserved. In this setting, a large prospective trial documenting that 
treatment guided by MRI-based risk stratification improves out-
comes in this patient group is still very much expected.376
Otherwise, the MUSTT Trial suggested the value of EPS for im-
proving the SCD risk stratification, in the subgroup of ICM patients 
with a residual EF comprised between 30 and 40%.377
In addition, other non-invasive investigations like tissue Doppler 
Imaging (TDI) seem also to be of potential value in predicting VT/VF 
in ICM. Late diastolic velocity assessed by TDI, particularly when de-
tected in the inferior myocardial wall, seems to be a sensitive marker 
of future VT/VF.374 Finally, it is well known that non-sustained ven-
tricular tachycardia (NSVT) is a marker of increased risk of VT/VF 
and arrhythmic death. During the convalescent phase after an acute 
coronary syndrome, NSVT seems to be associated with an increased 
risk of cardiovascular death, most marked within the first 2 months 
after detection.375 The use of such investigations could help to de-
tect those patients at higher risk of VT/VF, more particularly during 
the early phase after an acute coronary event. Specific measures like 
prolonged monitoring or use of wearable cardiac defibrillator could 
be undertaken on an individual patient-case basis. However, more 
solid data are needed to support such recommendations broadly.
5.2 | Patients with non-ischaemic heart failure
Patients with non-ischaemic 
heart failure Class References
MRI may be considered for 
further risk stratification of 
sudden death in patients with 
non-ischaemic cardiomyopathy 
who do not otherwise meet an 
indication for ICD implantation
378
EPS may be considered for further 
risk stratification of sudden 
death in selected patients with 
non-ischaemic cardiomyopathy 
who do not otherwise meet an 
indication for ICD implantation
378
Patients with non-ischaemic HF represent a broad and diverse 
group of patients including those with progressive and infiltrative 
forms of cardiomyopathies. For this reason, the risk of developing 
VT in non-ischaemic HF is difficult to accurately predict in this group 
of patients. Subsequent sections in this document will address spe-
cific conditions that have unique risk profiles including inflammatory 
cardiomyopathies, congenital heart disease, arrhythmogenic cardio-
myopathy, and Chagas’ disease.
Prior investigations into identification of the risk of developing 
VT in non-ischaemic cardiomyopathy focused on the risk of SCD 
and the role of the implanted defibrillator for primary prevention. 
The DANISH trial61 reported no survival benefit from prophylac-
tic ICD implantation in the overall cohort. Implantable cardiovert-
er-defibrillator reduced SCD to half, and subgroup analysis showed 
that in patients younger than 68 years, survival was prolonged 
with an ICD. Although pooled analysis of the five primary preven-
tion trials (DEFINITE, SCD-HeFT, CAT, AMIOVIRT, COMPANION, 
Primary prevention of VT/VF in 
patients with ICM and LVEF >35% Class References
ICM substrate and ischaemic triggers 
for VT/VF must be evaluated when 
appropriate (coronary angiogram, 
functional ischaemic evaluation by 
nuclear scan, stress-echocardiography 
or MRI)
54,70,71
EPS and non-sustained VT evaluation 
could be considered to improve VT/
VF risk stratification in patients with 
relatively preserved LVEF, particularly in 
the convalescent phase (first 2 months) 
after an acute coronary syndrome
312,374,375
Heart rate variability (HRV), LVP, 
baroreflex sensitivity, QT-interval 
dispersion, T-wave alternans and 
heart rate turbulence have not 
been evaluated adequately in this 
population for generalized use
73,372,373
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and DANISH; n = 2970) revealed that ICD therapy was superior to 
medical therapy in patients with non-ischaemic cardiomyopathy 
with decreased cardiac function, these trials were judged globally 
negative.379
In a limited number of studies outside of these clinical trials, the 
role of EPS or non-invasive programmed stimulation has revealed 
inconsistent results.378 More recently, the role of cardiac MRI for 
definition of scar and potential substrate has emerged as a powerful 
risk stratification tool in observational studies.49,380,381 Genetic test-
ing is also useful in patients with decreased cardiac function with 
conduction disturbance (i.e. LMNA mutations).
In summary, non-ischaemic HF includes a diverse group of pa-
tients with reduced ventricular function due to cardiomyopathies 
from different aetiologies, and at high risk for VT. Reduced cardiac 
function remains a powerful predictor of VT and appropriate ICD 
therapy in these patients as a primary prevention. Cardiac MRI and 
EP testing shows promise in some subsets. Further characterization 
based on the type of cardiomyopathy leading to HF shows the most 
promise for accurate assessment of VT risk.
5.3 | Patients with inflammatory cardiomyopathies
Patients with inflammatory 
cardiomyopathies Class References
In patients with non-ischaemic 
heart disease who present with 
ventricular arrhythmias, use 
of cardiac MRI or cardiac PET 
can help delineate aetiology of 
non-ischaemic cardiomyopathy, 
initiate aetiology-driven 
treatment, and evaluate 
prognosis.
52,53,380
Inflammatory cardiomyopathies encompass a broad spectrum 
of disorders characterized by myocardial inflammation as the pri-
mary cause of cardiac dysfunction. This includes viral myocarditis 
(commonest cause), cardiac sarcoidosis, giant cell myocarditis, au-
toimmune myocarditis associated with underlying connective tissue 
diseases, eosinophilic cardiomyopathies, and Chagas disease (ad-
dressed in a separate chapter).
In patients who present with ventricular arrhythmias and diag-
nosed with non-ischaemic cardiomyopathy, the incidence of inflam-
matory cardiomyopathy may be as high as 50%.382 Therefore, it is 
important to consider inflammatory cardiomyopathies as an under-
lying cause, given that these conditions may benefit from specific 
aetiology-driven treatments. Infectious causes of myocarditis in-
clude viral (e.g. parvovirus B19 and human herpes virus 6 genomes 
that predominate in inflammatory cardiomyopathies, other cardio-
tropic viruses include enteroviruses, adenoviruses, hepatitis C, and 
human immunodeficiency viruses) and uncommonly bacterial and 
other causes depending on the geographical area and immunosup-
pression status. Myocarditis associated with connective tissue and 
autoimmune diseases encompass systemic lupus erythematosus, 
scleroderma, rheumatoid arthritis, dermatomyositis, polymyositis, 
cardiac sarcoidosis and giant cell myocarditis. Drug reactions may 
also cause hypersensitivity myocarditis.382,383 In cases of an estab-
lished cause of inflammatory cardiomyopathy, the focus should be 
on treating the underlying inflammatory condition. In the case of 
cardiac sarcoidosis, retrospective series have shown that specific 
treatment with immunosuppressive therapy can increase VT free 
survival.52
Cardiac MRI scan is the gold standard for diagnosing myocarditis 
and inflammatory cardiomyopathies. Oedema, hyperaemia, and LGE 
form the diagnosis of acute myocarditis. Further diagnostic informa-
tion is gleaned from T1 and T2 mapping techniques. Although no 
specific LGE pattern on MRI is diagnostic of cardiac sarcoidosis, LGE 
is most often observed in basal segments, particularly of the septum 
and lateral wall, and usually in the mid-myocardium and epicardium 
of the myocardium384–386
The presence of LGE significantly increases risk of adverse car-
diac events. The presence of LGE on cardiac MRI increased the risk of 
ventricular arrhythmias and death by greater than 20 fold in patients 
with EF >35% and extracardiac sarcoidosis compared to sarcoid pa-
tients without evidence of LGE on MRI, and the burden of LGE was 
associated with higher rates of death/VT.387 In a meta-analysis of 
155 patients with systemic sarcoidosis who underwent cardiac MRI 
for work-up of cardiac sarcoidosis, the presence of LGE was associ-
ated with hazard ratio of 31.6 for death, aborted SCD, or appropriate 
ICD discharge and provided superior prognostic information as to 
compared to other clinical and functional characteristics, including 
LVEF.51
In addition, the distribution of LGE confers important prognos-
tic information, with mid-wall anteroseptal LGE representing a more 
malignant form compared to a sub-epicardial inferolateral wall LGE 
pattern.388,389 Inflammatory biomarkers, such as C-reactive protein, 
are typically lower in this group with septal LGE, but biomarkers of 
myocardial damage such as troponin are typically higher, suggestive 
of a subset with less inflammation but greater myocardial injury. 
F-fluorodeoxyglucose (FDG)-PET is advantageous for detecting 
active inflammation in cardiac sarcoidosis, and a mismatch of FDG 
and perfusion and involvement of the right ventricle predicts ad-
verse cardiac events and ventricular arrhythmias, respectively.53 
Endomyocardial biopsy is performed in cases where a histological 
diagnosis is required to confirm cardiac sarcoidosis or giant cell myo-
carditis, with its yield enhanced by electrogram guidance. Active 
viral genomes may also be identified by biopsy, which can differ sig-
nificantly from peripheral serological tests.383,390
Little data exist on how to assess risk of VT/VF in inflammatory 
cardiomyopathies. Besides EF, which is used for all non-ischaemic 
aetiologies, no randomized studies have evaluated other parameters 
or even EF as a predictor of VT in different inflammatory cardiomy-
opathies. In particular, certain inflammatory cardiomyopathies may 
carry higher risk than others (sarcoidosis vs. viral myocarditis). Risk 
of ICD therapy may be as high as 15% per year in biopsy proven 
cardiac sarcoidosis patients.391 Although randomized data on use of 
higher EF in these patient populations is lacking, given risk of VT 
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noted in retrospective studies, use of MRI and cardiac PET to evalu-
ate aetiology of non-ischaemic heart disease is warranted, and treat-
ment of inflammation to reduce risk of VT is advised. Furthermore, 
cardiac PET and MRI can be used to assess for recurrent inflamma-
tion or progression of disease on treatment.
5.4 | Patients with congenital heart disease
Ventricular arrhythmias in patients with congenital heart disease 
(CHD) may be observed in two different groups: the paediatric age 
group and adults with repaired congenital defects group.398 In the 
paediatric age, life-threatening VT is rare both prior to and after sur-
gery. Ventricular tachyarrhythmia is seen in only 1.8% of children 
undergoing an EPS,392 is usually associated with structurally normal 
heart and most frequently comes from the right outflow tract and 
left outflow tract and sinuses of Valsalva.
In paediatric patients with CHD, the haemodynamic and elec-
trophysiologic factors related to each disease state and associated 
therapeutic interventions play an important role in the develop-
ment of VT, with ventricular overload, surgical scars and patches, 
baffles and conducts, ventricular dysfunction, and previous con-
duction defects among the most relevant.393 In the early post-op-
erative stage, Van Hare et al. reported only 3 patients with VT out 
of 580 undergoing paediatric surgery and the most important risk 
factor was the surgical procedure.392 Sustained VT may arise in 
the setting of myocardial ischaemia or infarction and may be facil-
itated by disruption of the ventricular myocardium caused by scar 
due to ventriculotomy, fibrotic tissue, or ventricular dilatation.394
In adult patients with CHD, VTs are mainly observed after cor-
rection of tetralogy of Fallot (TOF) and left ventricular outflow tract 
defects but may also arise in other defects as transposition of the 
great arteries with atrial switch, univentricular hearts, double-outlet 
RV, and ventricular septal defects. Older age at surgery, poor hae-
modynamic status, and prolongation of the QRS represent the most 
common risk factors. In patients with TOF, the correlation of residual 
haemodynamic lesions and right ventricular dysfunction with risk of 
VT or SCD has been extensively established.395,396 Potentially treat-
able residual haemodynamic problems, pulmonary hypertension, 
elevated end-diastolic pressures, and reduced ventricular function 
should be treated as part of the arrhythmia management. Particularly 
in this group, frequent PVCs, QRS 180 milliseconds or more, palliative 
systemic to pulmonary shunts, syncope, atrial tachycardia, decreased 
LVEF, dilated right ventricle, severe pulmonary stenosis or regurgi-
tation are risk factors for sustained VT, and inducible sustained VT 
correlates with increased risk of SCD.397,399 EPS might be considered 
for risk assessment of VT/VF in this group of patients with high-risk 
clinical characteristics and frequent ventricular arrhythmias.328
5.5 | Patients with inherited arrhythmia diseases 
(inherited channelopathies and inherited structural 
diseases including arrhythmogenic right ventricular 
cardiomyopathy)
Patients with inherited arrhythmia disease are without doubt at 
increased risk for ventricular arrhythmias, including SCD. The extent 
to which this is pertinent and predictable is different for the various 
conditions.
The main primary inherited arrhythmia syndromes, i.e. the ‘chan-
nelopathies’ are LQTS, Brugada syndrome and CPVT.402 Patients 
that are symptomatic (syncope, cardiac arrest) at the time of pre-
sentation are at highest risk, with arrhythmic syncope representing 
a sentinel sign of risk, and resuscitated cardiac arrest reflecting the 
highest risk cohort.97 Despite major social impact on perceived risk, 
family history is not of major importance in all three diseases.
Risk for ventricular arrhythmias 
in patients with congenital heart 
disease Class References
In the paediatric patient with CHD, 
ventricular overload, surgical scars 
and patches or baffles, ventricular 
dysfunction, and previous 
conduction defects are recognized 
risk factors for VT.
392–394
In adult patients with CHD, older 
age at surgery, poor haemodynamic 
status, and prolonged QRS represent 
the most common risk factors for 
ventricular arrhythmias.
393–395
In adult patients with CHD, VTs are 
mainly observed after correction 
of tetralogy of Fallot (TOF) and left 
ventricular outflow tract defects.
395–397
In patients with TOF, residual 
haemodynamic lesions and 
ventricular dysfunction represent 
the most important risk factors for 
VT or SCD.
395–397
In patients with TOF, frequent PVCs, 
QRS >180 ms, palliative systemic to 
pulmonary shunts, syncope, atrial 
tachycardia, decreased LVEF, dilated 
right ventricle, severe pulmonary 
stenosis or regurgitation, are risk 
factors for sustained VT.
395–397
Risk for ventricular arrhythmias in 
patients with inherited arrhythmia 
diseases Class References
Patients with primary inherited 
arrhythmia syndromes and 
cardiomyopathies should undergo 
risk stratification that integrates 
clinical presentation, family history, 
and non-invasive diagnostic testing
400
Select patients with primary 
inherited arrhythmia syndromes and 
cardiomyopathies may benefit from 
electrophysiologic testing to refine 
non-invasive risk stratification
401
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In LQTS, clearly defined disease-specific risk factors are the 
extent of resting QT prolongation, documentation of arrhythmias 
and gene and even mutation specific associated risk.403 In CPVT, 
the extent of the arrhythmic response of an exercise test predicts 
events, including breakthrough symptoms on therapy.404 It follows 
that risk assessment requires a baseline ECG and an exercise test 
in both conditions, with potential value of ambulatory monitoring. 
Assessment should include asymptomatic patients often identi-
fied during family screening or after incidental unrelated medical 
evaluation.
In Brugada syndrome, there is uncontested agreement that 
symptomatic patients (arrhythmic syncope, cardiac arrest) are 
at high risk for SCD, requiring aggressive therapy with an ICD in 
most circumstances. Risk stratification in asymptomatic individu-
als with a spontaneous type 1 ECG is much less clear, involving a 
variety of ECG characteristics and potential value of programmed 
electrical stimulation (PES).405,406 ECG parameters that have been 
associated with increased risk include QRS fragmentation, early 
repolarization, Brugada type changes in non-anterior precordial 
leads and a positive signal-averaged ECG. Programmed electrical 
stimulation with a non-aggressive stimulation protocol may be of 
importance, although the risk of an inducible patient is only mar-
ginally different from a non-inducible patient.77 In LQTS, CPVT, and 
Early Repolarization syndrome, PES is of no importance. The pres-
ence of a SCN5a mutation may contribute to risk in Brugada syn-
drome.407 Early repolarization syndrome, short-coupled idiopathic 
VF (SCIVF), and SQTS are uncommon causes of cardiac arrest and 
sudden death. Though the early repolarization pattern conveys a 
small increase in risk, the only patients where the risk is substan-
tive to consider intervention are those with prior cardiac arrest or 
syncope with a positive family history. There are no validated risk 
models in SQTS and SCIVF.
In the cardiomyopathies, i.e. the secondary inherited arrhyth-
mia syndromes, risk stratification is also disease specific. In hyper-
trophic cardiomyopathy (HCM) septal thickness, the hallmark of 
the disease is an important contributor to risk. Other risk factors 
include left atrial dimension, left ventricular outflow tract gradi-
ent (all echocardiographic parameters), the presence of ventricular 
arrhythmias on ambulatory monitoring (Holter) or documentation 
otherwise, symptoms (i.e. unexplained syncope, palpitations as-
sociated with near syncope), demographic factors (age in partic-
ular), and family history. All these factors are included in the ESC 
risk score calculator,408 which is readily available in an online tool 
(http://www.doc2do.com/hcm/webHCM.html), and applied after 
standard imaging, exercise testing and ambulatory monitoring. 
Validation of the ESC risk calculator is not compelling, and con-
sideration of imaging and exercise blood pressure response pa-
rameters have also been used in borderline cases. In inherited, i.e. 
non-ischaemic, dilated cardiomyopathy, the genetic background is 
very important, with LMNA (Lamin A/C) and PLN (Phospolamban) 
leading to highly arrhythmic substrates.123,409–411 Of course, re-
duced LVEF and the presence of ventricular arrhythmias during 
ambulatory monitoring are important risk factors as well. In 
arrhythmogenic right ventricular cardiomyopathy (ARVC) or ar-
rhythmogenic ventricular cardiomyopathy (ACM), symptomatic ar-
rhythmic events identify the patient at highest risk, and major risk 
factors include age, male sex, unexplained syncope, non-sustained 
VT, number of anterior precordial leads with T wave inversion, and 
severe right or left ventricular dysfunction.412 Hence, as for the 
other cardiomyopathies, echocardiographic imaging, and Holter 
monitoring is required for risk assessment. In all cardiomyopathies, 
MRI is becoming increasingly important, in particular to show the 
presence of fibrosis (HCM, DCM, ACM) and assess left and right 
ventricular function. Genetic testing should be considered in any 
patient with a phenotype suggesting an inherited cardiomyopathy 
and in dilated cardiomyopathy with a suggestive family history or 
onset at an early age that is otherwise unexplained (i.e. not myo-
carditis, sarcoidosis etc.). Genetic testing is largely for diagnosis, 
and only informs risk when a high-risk form of cardiomyopathy is 
diagnosed, such as PLN or LMNA.
5.6 | Risk stratification in patients with 
arrhythmogenic cardiomyopathy, specified for 
arrhythmogenic right ventricular cardiomyopathy
Risk stratification of ventricular 
arrhythmias in ARVC Class References
In patients with ARVC, history of 
aborted sudden death, sustained 
ventricular arrhythmias, and 
severe right and/or left ventricular 
dysfunction identify a high risk of 
cardiac death
413,414
In patients with ARVC, advice 
to not perform high-level or 
endurance exercise should be 
given.
415,416
Clinical factors including age, male 
sex, unexplained syncope, non-
sustained VT, number of anterior 
precordial leads with T wave 
inversion, and genetic mutation 
status can be used for prognostic 
stratification of patients with 
ARVC
413,414
In patients with confirmed ARVC, 
regular Holter monitoring and 
imaging for assessment of 
ventricular function may be useful.
415,416
A detailed history of exercise 
intensity and duration may be 
helpful in patients with ARVC as 
exercise level may represent a 
modified risk factor of adverse 
cardiovascular events and disease 
progression
417
In arrhythmogenic right ventricular cardiomyopathy (ARVC or ), 
the most important features characterized as the high arrhyth-
mic risk include the electric instability (i.e. sustained ventricular 
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arrhythmia [VA]), genotype-positive, extent of structural involve-
ment, cardiac syncope, the presence of multiple mutations, and 
the history of competitive or endurance exercise.413,414 In patients 
without prior VA, an available online prediction model, derived 
from the largest cohort of ARVC patients, using readily available 
clinical parameters was devised to estimate the risk of VA and to 
guide the decisions of ICD implantation as primary prevention 
(www.arvcr isk.com).418
There is a dose-dependent relationship between endurance ex-
ercise and the disease onset and progression in confirmed ARVC 
patients. Exercise restriction is recommended to prevent disease 
progression and SCD in confirmed ARVC patients with ICD415 and 
genotype-positive relatives.416 In general, high-level or endurance 
exercise is not recommended in confirmed ARVC patients or at risk.
Ambulatory ECG monitoring is crucial to detect the PVCs burden 
or the presence of non-sustained VT, which also provide prognostic 
information in ARVC.417 All positive criteria of signal-averaged ECG 
non-invasively identifies the slow conduction of myocardium and 
has been proven for risk stratification in patients with suspicion or 
confirmed ARVC.419
Echocardiography and cardiac MRI provide accurate measure-
ments of right ventricular global and regional dysfunction and right 
ventricular volume and regional/global ventricular function, as the 
important variable for assessment of right and left ventricular dis-
ease. The Task Force Criteria did not include cardiac MRI measures 
of right ventricular myocardial fat or LGE in order to risk stratify the 
ARVC.420 In summary, abnormal cardiac MRI was an independent 
predictor of clinical events with a cumulative effect of the abnor-
malities including morphology, wall motion, and fat/fibrosis in ARVC 
patients.419
An EPS may provide help distinguish ARVC from idiopathic 
right ventricular outflow tract (RVOT) VT. Additionally, positive 
inducibility on program ventricular simulation is not a perfect sur-
rogate marker neither for ARVC diagnosis, nor the decision of ICD 
implantation.413,414 EPS may be beneficial to identity patients that 
may benefit from ablation. In this setting, EPS with high-dose iso-
proterenol may help differentiate patients with idiopathic VT or 
ventricular premature beats from those with ARVC.421 The posi-
tive inducibility of EPS can predict any ICD therapy, including VF, 
and can be an important parameter for risk stratification in patients 
with ARVC.
ARVC is considered to have desmosome dysfunction. Genetic 
causes of isolated or predominantly RV arrhythmia and structural 
abnormalities are most commonly associated with desmosomal 
gene variants. Positive genetic test contributes up to 50% of the 
diagnosis of ARVC, however, in confirmed ARVC patients, limited 
evidence of clinical actionable risk stratification or use of man-
agement of disease. Several gene variants have been reported 
in patients with left ventricular or biventricular arrhythmia. Left 
ventricular dysfunction is most often present in patients with 
ARVC with pathogenic variants in Lamin A/C, or variants in the 
PLN and TMEM43 genes, and followed by variants in DSP, DSG2/
DSC2.400,401,422,423
5.7 | Patients with Chagas disease
Patients with Chagas disease Class References
The Rassi score is useful in 
assessing risk of death in 
Chagas disease patients
347,348
In patients with syncope and a 
BBB, an invasive EPS is useful 
in assessing risk of sustained 
ventricular arrhythmias
349,350
When available, cardiac 
MRI with LGE should be 
considered to evaluate for 
arrhythmogenic substrate as 
part of a risk stratification 
strategy in those patients 
with cardiomyopathy
351–354
Chagas disease is an infectious disease affecting 10 million 
people around the world and 100 million more are at risk of this 
infection. Due to migration, it is estimated 750 000 infected car-
riers live in the USA or Europe.355,424 VA, especially sustained VT 
is closely related to high mortality, sudden death (SCD) happening 
in 17%-50% of chronically ill patients.356 Based on the identifica-
tion of different risk factors, Rassi et al. developed a mortality risk 
score (Table 3).347 Patients with HF, NYHA Class III/IV and NSVT 
on Holter and patients in NYHA Class I/II, with left ventricular 
dysfunction and NSVT on Holter are at the highest risk of death 
and should be regarded as candidates for aggressive therapeutic 
management.
Conversely, patients with an abnormal ECG (right or left 
bundle branch conduction disorders) but in NYHA Class I/II HF 
without left ventricular dysfunction or NSVT on Holter are at 
lower risk of death. These patients should be followed up annu-
ally or biannually. Between these two extremes, some patients 
are at intermediate risk and their treatment strategies should be 
individualized.
TA B L E  3   Rassi score
Risk factor Points
NYHA Classes III or IV 5
Cardiomegaly (chest radiograph) 5
Segmental or global wall motion abnormality (2D 
echocardiogram)
3
Non-sustained ventricular tachycardia (24-h Holter) 3
Low QRS voltage (ECG) 2
Male sex 2
Total points
Total mortality (%)
Risk5 years 10 years
0-6 2 10 Low
7-11 18 44 Intermediate
12-20 63 84 High
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Sustained VT has been reported as the main cause of syncope 
in patients with non-documented recurrent syncope and bundle 
branch block (BBB). In these cases, an EPS has been recommended 
for diagnosis elucidation.349 A finding of scar by LGE by cardiac MRI 
in patients with Chagas disease is considered a strong predictor of a 
combination of sustained VT and death.357
6  | HOW TO A SSESS RISK FOR 
ADVERSE OUTCOMES IN PATIENTS WITH 
VENTRICUL AR TACHYARRHY THMIA
6.1 | Risk for appropriate and inappropriate 
implantable cardioverter-defibrillator therapies
ICD therapies are associated with an increase in mortality.371,425–427 
A single ICD shock is associated with a two- to five-fold increase 
in mortality, and progressive heart failure has been reported the 
most common cause of mortality among these patients.428–430 ICD 
therapies are classified as appropriate, inappropriate, avoidable, 
and phantom.371,431,432 Approximately 12%-17% of patients receive 
inappropriate ICD shocks.425,428–430 Both appropriate and inappro-
priate shocks area associated with an increase in mortality and can 
significantly lower quality of life. Thus, identifying predictors of ICD 
therapies may improve quality of life and long-term outcomes in pa-
tients with ICDs.
6.1.1 | Appropriate shock predictors
A previous episode of sustained VT correlates with high rate of ap-
propriate shocks.433–436 A higher risk of appropriate therapy was 
seen in a secondary prevention ICD group when compared with 
a primary prevention ICD group at 5-year follow-up, while the 
rate of inappropriate therapy was comparable.437 Several studies 
have shown male sex as an independent risk factor for appropri-
ate ICD therapies.438 Women are 30%-50% less likely to receive an 
appropriate shock,439–442 and this difference is more pronounced 
among CRT-D recipients.443–445 However, most of studies have 
shown similar mortality rates in both genders after ICD implan-
tation.438–445 AF is common in patients with left ventricular dys-
function; the prevalence can increase up to 50%. Worsening AF 
subtype increases the risk for both appropriate shocks and overall 
mortality.446–449
Other risk factors implicated to increase the risk of appropri-
ate shocks are diabetes,446,450 elevated baseline NT-proBNP and 
BNP,451 NSVT,448,452 left atrial diameter,446,452 and impaired renal 
function.453 Data from SCD-HeFT and MADIT II trials have found 
a higher NYHA class, a lower LVEF, lack of use of beta-blocker ther-
apy and single-chamber ICD as significant independent predictors 
for appropriate ICD shocks.454 Data from the Danish ICD Registry 
showed that LVEF <25% predicted an increased risks of both appro-
priate and inappropriate therapies.455
6.1.2 | Inappropriate shock predictors
The presence of supraventricular tachycardias, in particular AF, has 
been reported as the most common risk factor for inappropriate ICD 
shocks.429,447,448 Another risk factor associated with inappropriate 
shock is younger age.451,453,454 Inappropriate shocks secondary to 
AF/atrial flutter are associated with increased mortality while in-
appropriate shocks related to sinus tachycardia or non-arrhythmic 
events like noise, artefact, and oversensing have shown similar sur-
vival as compared to those who do not receive a shock.456 Studies 
have failed to establish the superiority of dual-chamber ICD over 
the single chamber in reducing inappropriate shocks.457,458 The 
Danish ICD Registry showed a two-fold increase in the risk of in-
appropriate shocks associated with a dual-chamber ICD.459 Device 
technologies and programming, i.e. prolonged detection time, high 
rate programming, and better discrimination algorithms have mark-
edly reduced the risk of inappropriate therapies.371,459,460
6.2 | Risk for heart failure incidence and 
progression
Risk for heart failure incidence 
and progression Class References
Periodic monitoring of PVC burden 
(every 6 months) and LVEF and 
dimensions are useful in patients 
with frequent, asymptomatic 
PVCs and a normal LVEF and 
dimensions
461
PVC burden exceeding 20% is 
associated with a higher risk of 
PVC-related cardiomyopathy
462–464
PVC burden lower than 10% is 
associated with a lower risk of 
PVC-related cardiomyopathy
465,466
In patients with PVC-related 
cardiomyopathy, absence of 
LGE on cardiac MRI may be 
used to identify patients with 
a favourable prognosis of left 
ventricular systolic function 
recovery
467–469
Tachycardia-induced cardiomyopathy is a reversible cause of HF 
and impaired left ventricular function. Ventricular rhythms causing 
tachycardia-induced cardiomyopathy include VT, fascicular tachy-
cardia, PVCs, and even persistent rapid DDD pacing. Left ventricu-
lar systolic function improves or normalizes and symptoms resolve, 
when tachycardia is corrected or controlled with medication or phar-
macologic or non-pharmacologic rhythm control strategies.
Sustained monomorphic VT less commonly causes tachycar-
dia-induced cardiomyopathy as compared to supraventricular tachy-
cardias, since sustained VT is most often associated with some 
form of structural heart disease. When VT does lead to tachycar-
dia-induced cardiomyopathy, it is by definition idiopathic and most 
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commonly originates from the RVOT, left ventricular outflow tract, 
or coronary cusps. If these arrhythmias become persistent or high 
burden, they may cause reversible left ventricular dysfunction.470
A single centre series reported that 11% of patients who pre-
sented with frequent PVCs also had sustained monomorphic VT and 
7% of those patients had tachycardia-induced cardiomyopathy. The 
presence of repetitive monomorphic VT was a significant predic-
tor of tachycardia-induced cardiomyopathy development, particu-
larly when it was the predominant arrhythmia on 24-hours Holter 
monitoring.464
PVCs are very common and usually do not require treatment in 
the absence of symptoms. However, in the clinical setting of trou-
blesome symptoms, or when PVCs trigger polymorphic VT or cause 
cardiomyopathy, proper treatment is critical. The concept of PVC-
induced cardiomyopathy was first proposed by Duffee et al,463 who 
observed a small group of patients with cardiomyopathy recover 
normal left ventricular function after pharmacological suppression 
of frequent PVCs.
Baman et al462 reported on 174 consecutive patients referred 
for PVC ablation, 54 of whom had depressed left ventricular func-
tion. The authors concluded that although PVC-related cardiomy-
opathy may occur in patients with less PVCs, “in the presence of 
a PVC burden ≥24%, it may be helpful to suppress the PVCs by 
catheter ablation or drug therapy to avoid the development of car-
diomyopathy.” However, Aki Lee et al., demonstrated a high rate 
of resolution of frequent PVCs among untreated patients with 
normal left ventricular function and minimal symptoms. A strategy 
of active surveillance is appropriate for the majority of patients 
with frequent idiopathic PVCs in association with preserved LVEF, 
owing to the low risk of developing left ventricular systolic dys-
function and the high rate of spontaneous resolution. Periodic 
monitoring of PVC burden and LVEF and dimensions can be useful 
in patients with frequent, asymptomatic PVCs and a normal LVEF 
and dimensions.461
It has become clear that comparative effectiveness trials are 
needed to understand what the best treatment approach is for 
patients with frequent PVCs and cardiomyopathy. A pilot multi-
centre study (PAPS: Prospective Assessment of PVC Suppression 
in Cardiomyopathy) is ongoing to better understand the prevalence 
of frequent PVCs and CM, and prove the feasibility of a large-scale 
randomized clinical trial (not yet published).471
Several circumstances have been associated with PVC-induced 
cardiomyopathy, including the PVC burden, asymptomatic sta-
tus, duration of a high PVC burden, PVC QRS width >150 milli-
seconds, interpolated PVCs, epicardial origin, and male gender. 
However, no prospective longitudinal assessments have been con-
ducted that definitively prove their causal relation to PVC-induced 
cardiomyopathy.472
The diagnosis of tachycardia-induced cardiomyopathy or PVC-
related cardiomyopathy can be challenging and the role of imaging 
modalities in the characterization of myocardial tissue as part of the 
diagnostic workup is limited.467 Cardiac MRI with LGE can accurately 
identify the presence and extent of myocardial scar and has become a 
first-line non-invasive imaging modality for the aetiologic assessment 
of primary cardiomyopathies and/or left ventricular systolic dysfunc-
tion, and could identify early stage of the structural heart disease.
6.3 | Risk for death in ventricular 
tachyarrhythmia patients
Risk for death in VT patients (including 
risk for SCD) Class References
Risk for SCD should be judged in 
each patient on a case-by-case basis 
and risk considered as a continuous 
variable rather than a dichotomized 
variable (high or low risk may change)
473–475
Individual risk assessment needs to be 
dynamic as the type and severity of 
risks can change over time (repeated 
measurements need to be made over 
time)
476
Risk assessment may include 
consideration of mode of death 
as the relative risk of non-sudden, 
non-cardiac death, sudden cardiac 
death, and non-sudden cardiac death 
is influenced by aging and worsening 
cardiomyopathy and cardiovascular 
risk factors
370,477,478
Risk prediction of death in VT patients has used numerous 
non-invasive and invasive markers including: clinical markers, mode 
of initial clinical presentation (e.g. sustained stable monomorphic 
VT, ventricular flutter, or VF), biomarkers, ECG abnormalities (e.g. 
left bundle branch block), heart rate variability, signal-averaged ECG, 
ambulatory ECG-based frequency domain T wave, microvolt level-T 
wave alternans, heart rate turbulence, heart rate deceleration, QT 
dispersion, cardiac autonomic function, echocardiographic evalu-
ation of LVEF, left ventricular diameter, left ventricular mechanical 
dispersion by tissue Doppler, strain and velocity parameters to eval-
uate regional LV function, exercise testing to evaluate functional sta-
tus, MRI to measure scar burden, and EPS to assess for inducibility 
of VT. Most of these tests and markers were applied to patients at 
risk of SCD and not patients who already have VT. Thus, their use for 
predicting death in a patient with VT is unknown.
The main sources of information about risk for SCD in patients 
with VT are from two studies from the era prior to widespread ICD 
use,479,480 the control groups (patients who did not receive ICDs) 
in the primary prevention ICD studies (MUSTT, MADIT, MADIT II, 
SCD-HeFT, DANISH, DEFINITE, CABage-PATCH, IRIS, DINAMIT) as 
well as analysis of large data samples from registries since ICD ap-
proval from Europe, Canada, and the USA.70,481,482 These data have 
been extensively reviewed to better characterize which variables 
predict the development of SCD and death in high-risk patients. Data 
from secondary prevention studies (AVID, CIDS, CASH) provide ad-
ditional information about risk of death in patients who have had 
VT. Another source of information is the International VT Ablation 
Center Collaborative Study Group which analysed a large group of 
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patients with VT (approximately 2000 patients from 12 international 
sites) undergoing catheter ablation.483 Finally, a third useful source of 
data is the Seattle Heart Failure model developed by Wayne Levy and 
his colleagues who analysed data from a large sample of heart failure 
patients to predict risk of death and SCD as well as create a model for 
predicting benefit from ICD therapy.484 This model has been prospec-
tively validated among five additional study cohorts of almost 10 000 
heart failure patients. It is important to recognize that the causes of 
death can change over time. For example, the risk of death in a patient 
with post-MI VT may be largely due to mechanical problems (VSD, 
mitral regurgitation, heart failure) in the first several weeks to months 
after MI and then 3-6 months later the risk of arrhythmic death may 
be much higher due to matured scar-mediated substrate.
Based on these studies, the risk factors for death in VT patients 
include increasing NYHA class, old age, female gender, electrical 
storm, frailty, diabetes mellitus, AF, chronic kidney disease, chronic 
obstructive lung disease, peripheral arterial disease, advanced HF, 
non-ischaemic cardiomyopathy, lower EF, multiple different VT mor-
phologies, use of haemodynamic support devices during VT abla-
tion, and poor functional status. These risk factors can be divided 
into risk factors related to non-cardiac disease (e.g. renal function, 
diabetes, COPD, peripheral arterial disease) which are powerful and 
determine mortality, and cardiac risk factors (ischaemic vs. non-isch-
aemic aetiology, multiple morphologies of VT, EF, and functional 
status). There was an interaction between variables, such as higher 
rates of both VT recurrence and mortality, which was observed in 
patients with lower EF and worse NYHA failure status.483,484
6.4 | Risk of adverse outcomes in patients treated 
with catheter ablation
Risk of death or acute haemodynamic compromise in patients 
who undergo catheter ablation of ventricular arrhythmias is driven 
by patient-specific factors (comorbidities), procedural factors, and 
presentation of the patient. In a large retrospective multicentre reg-
istry, factors such as low EF, chronic kidney disease, VT storm, and 
unmappable VTs were associated with early mortality.489 As men-
tioned above, male sex is associated with occurrence of VT/VF and 
ICD shocks.490 As procedural factors are often difficult to determine 
prior to the procedure, various risk scores have been developed to 
assess risk of acute haemodynamic compromise and/or death in 
patients undergoing catheter ablation of VT. Of these, a modified ver-
sion of the Seattle HF Model and PAINESD score have been used in 
single centre and multicentre retrospective studies to evaluate risk of 
acute haemodynamic compromise or death post-procedure.486,487,489 
The Seattle HF Model incorporates, amongst other variables, age, 
EF, blood pressure, weight, gender, HF medications, blood electro-
lyte, and haemoglobin levels as well as NYHA to predict mortality. 
A modified version of this model which incorporates VT storm and 
ICD shocks was recently reported to be potentially more useful in 
predicting 6 months survival in patients who undergo VT ablation.488 
The PAINESD score incorporates pulmonary disease, age, presence 
of ischaemic cardiomyopathy, NYHA, EF, VT storm, and diabetes and 
assigns a score between 3 and 6 to each of these patient characteris-
tics. In retrospective studies, patients with a PAINESD score greater 
than 15 had a 24% risk of acute haemodynamic compromise and a 
significantly higher risk of mortality.487,489 Use of these risk scores 
can be important in discussion of risks and benefits in patients un-
dergoing catheter ablation and may help determine need for haemo-
dynamic support during the procedure. However, larger multicentre 
prospective studies are required. It is important to note that patients 
with lower EF and NYHA Class IV HF may still benefit from success-
ful catheter ablation of VT, and freedom from VT after successful 
ablation is associated with improved mortality.483,491
With regard to VT recurrence, in addition to patient related co-
morbidities, large single centre and multicentre studies have shown 
that the risk of VT recurrence is driven by the underlying aetiol-
ogy, particularly in patients with non-ischaemic heart disease, even 
after adjusting for other patient comorbidities.492–494 In particular, 
patients with Lamin A/C cardiomyopathy, hypertrophic cardiomy-
opathy, cardiac sarcoidosis, and valvular cardiomyopathy appear to 
be at higher risk for VT recurrence after catheter ablation as com-
pared to idiopathic dilated cardiomyopathy.485,492 In addition, loca-
tion of scar seems to determine risk of VT recurrence post-catheter 
ablation.495 In this regard, endocardial ablation alone may be in-
sufficient in many non-ischaemic cardiomyopathies. In arrhythmo-
genic right ventricular cardiomyopathy, epicardial presence of scar 
can serve as the substrate for VT and combined endo-epicardal 
mapping and ablation or adjuvant epicardial ablation after endo-
cardial ablation is often required.496–499 Cardiac MRI with LGE can 
be used in assessment of scar location and may be beneficial in 
diagnosis and peri-procedural planning of VT ablation.500
Retrospective studies have shown that inducibility of VT at the 
end of ablation is associated with adverse outcomes, even after ad-
justing for other patient comorbidities. Non-inducibility of VT in 
ischaemic cardiomyopathy patients was shown to be associated with 
improved arrhythmia-free survival rates and all-cause mortality,501,502 
even after adjusting for other comorbidities. In addition, inducible 
clinical VT during non-invasive programmed electrical ventricular 
stimulation (PES) is associated with decreased 1-year VT free survival 
as compared with those who are not inducible (<30% vs. >80%)503
Patients who were non-inducible during non-invasive PES 
after ablation had a VT recurrence rate of only 9% at 1 year of fol-
low-up when both acute (at the end of the procedure) and late (at 
Risk of adverse outcomes in patients 
treated with catheter ablation Class References
The aetiology and severity of 
cardiomyopathy and inducibility of 
arrhythmias after VT ablation are 
useful in determining risk of recurrence 
of VT after catheter ablation
485
Risk scores in combination with 
procedural characteristics may be 
useful for assessing adverse outcomes 
associated with catheter ablation of VT
486–488
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6 days post-procedure) programmed stimulation were negative.504 
Therefore, PES may be used to guide redo ablation and address ICD 
programming.
Finally, although catheter ablation is generally performed after the 
occurrence of ICD therapies, two clinical trials reported the value of 
catheter ablation prior to or in conjunction with ICD implantation. The 
Prophylactic Catheter Ablation for Prevention of Defibrillator Therapy 
clinical trial randomized patients with spontaneous ventricular tachy-
cardia or fibrillation and history of myocardial infarction to ICD or ICD 
and catheter ablation. In this trial, 30-day mortality was zero along with 
a significant reduction in ICD therapies from 31% to 9% between the 
control (ICD) and intervention arms (ICD + catheter ablation).505 The 
Catheter Ablation of Stable Ventricular Tachycardia before Defibrillator 
Implantation in Patients with Coronary Heart Disease (VTACH) trial 
randomized patients with history of myocardial infarction and stable 
VT to catheter ablation followed by ICD implantation vs. ICD implanta-
tion alone and showed that catheter ablation reduced occurrence of VT 
or VF by 18% at 2 years of follow-up. These data imply that in patients 
who receive ICD for secondary prevention and have ischaemic heart 
disease, catheter ablation can be considered earlier, at the time of ICD 
implantation, to reduce future ICD therapies and prior to potential pre-
sentation with VT storm.506 The impact of early ablation (at the time of 
ICD implantation) on mortality was the subject of the BERLIN-VT clin-
ical trial, early results of which have indicated a lack of a difference in 
death or hospitalization for VT/VF in the deferred group (ablation after 
occurrence of third appropriate shock) vs. those who underwent pro-
phylactic ablation at the time of ICD implantation.507 It is important to 
note that in these studies, patients had a history of VT or VF. In patients 
with ischaemic heart disease undergoing ICD implantation for primary 
prevention of sudden cardiac death, prophylactic substrate modifica-
tion of scar by catheter ablation requires further investigation. In the 
Substrate Modification Study, patients randomized to ICD implantation 
plus VT ablation had similar time to VT recurrence as those who un-
derwent ICD implantation only. However, catheter ablation at the time 
of ICD implantation was associated with a greater than 50% reduction 
in total number of ICD therapies throughout the follow-up period.508
7  | HOW TO A SSESS RISK FOR ADVERSE 
OUTCOME IN PATIENTS WITH OTHER 
SPECIFIC C ARDIAC CONDITIONS
7.1 | Patients with ventricular premature 
contractions
Patients with ventricular 
premature contractions Class References
An evaluation of cardiac function 
and screening for heart failure 
symptoms should be considered 
in patients with frequent 
ventricular ectopy (>10 000 PVCs 
within 24 h or >10% over a more 
extended timeframe)
509
Patients with ventricular 
premature contractions Class References
An evaluation of cardiac function 
and screening for heart failure 
symptoms may be considered in 
patients with frequent multiform 
PVCs, PVCs with a QRS duration 
> 150 ms or PVCs with a coupling 
interval of <450 ms
510,511
Frequent PVCs can lead to cardiomyopathy and HF, and are as-
sociated with increased mortality.509 In addition, in some patients 
with an inherited arrhythmogenic cardiomyopathy, PVCs may be 
the initial clinical manifestation that leads to this diagnosis. An ini-
tial case series describing four patients who had reversal of car-
diomyopathy after amiodarone successfully suppressed a high PVC 
burden has resulted in the recognition for the potential reversibil-
ity of this condition.463 However, only a minority of patients with 
PVCs will develop symptoms or adverse sequelae. The factors that 
can potentially predict development of HF and increased risk of 
adverse outcomes include PVC frequency as well as characteristics 
of the PVC morphology and timing of the PVC coupling interval.
7.1.1 | Premature ventricular complex frequency
In a large cohort of patients, increased PVC frequency was associated 
with reduced LV function, a higher incidence of heart failure, and a 
higher risk of death. Specifically, compared to the lowest quartile of 
PVC frequency (<0.002%), the highest quartile (0.123% to 17.7%) in 
this cohort of patients with a structurally normal heart at baseline 
had a 31% increased risk of death over a follow-up of >13 years.509 
Other studies correlating frequency with PVC-induced cardiomyo-
pathy suggested a threshold effect observed at >20%, though there 
is no accepted cut-off that appears to be protective.462,510 In a study 
of 239 consecutive patients with apparently normal hearts, a PVC 
burden of >20 000 in 24 hours was associated with a reduced LVEF, 
whereas >10 000 but <20 000 showed LV dilation with preserved 
LVEF.512
7.1.2 | Premature ventricular complex morphology
In addition to PVC burden, the morphological features of the PVC 
have been evaluated. The width of the PVC QRS complex, perhaps 
reflective of dyssynchrony, has been associated with increased risk 
of developing PVC-induced cardiomyopathy.510,511 In these retro-
spective studies, patients with a PVC duration of >150 milliseconds 
appeared to require a lower burden for development of a cardiomyo-
pathy. A PVC duration of >153 milliseconds in patients with a >10% 
burden, was associated with an 82% sensitivity and 75% specificity 
for subsequent development of a cardiomyopathy. The presence of 
multiform PVCs has also been associated with the development of 
new onset heart failure.513
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7.1.3 | Premature ventricular complex 
coupling interval
One mechanism of PVC-induced cardiomyopathy may be due 
to ineffective mechanical contraction leading to adverse re-
modelling, possibly related to the timing of the PVC. However, 
there are only a few small studies evaluating this. In a retro-
spective cohort study of 510 patients, a PVC coupling interval 
of <450 milliseconds was associated with a reduced LVEF.514 
Another smaller study of 70 patients did not show any associa-
tion, though its power was limited.515 Another study specifically 
identified the presence of interpolated PVCs regardless of cou-
pling interval as associated with reduced LVEF.516 A short PVC 
coupling interval may also be an important determinant of VF, 
especially in patients with genetic or acquired early or abnormal 
repolarization.42,517,518
While the promise of effective treatment for reversing the po-
tential adverse cardiac effects of frequent PVCs remains a possibil-
ity, it remains unclear whether such patients can easily be identified. 
Most cardiologists accept the dose–response relationship of PVC 
burden and reduced cardiac function, although the precise thresh-
old for this effect remains unknown. There also is the potential for 
other factors aside from frequency alone, such as PVC QRS duration 
and coupling intervals, to influence adverse events associated with 
frequent PVCs.
7.2 | Patients with supraventricular tachyarrhythmia 
such as Wolff–Parkinson–White syndrome and focal 
atrial tachycardia
Patients with supraventricular 
tachyarrhythmia such as WPW 
syndrome and focal atrial 
tachycardia Class References
EPS, with the use of isoprenaline, 
is recommended to risk stratify 
individuals with asymptomatic 
pre-excitation who have high-risk 
occupations/hobbies, and those 
who participate in competitive 
athletics
519–521
EPS should be considered for risk 
stratification in asymptomatic 
pre-excitation patients without 
high-risk occupations or those 
who are not competitive athletes
519,521,522
Non-invasive screening with 
exercise testing, drug testing, 
and ambulatory monitoring 
may be considered for risk 
stratification in asymptomatic 
pre-excitation patients without 
high-risk occupations or those 
who are not competitive  
athletes
519,521,522
Patients with supraventricular 
tachyarrhythmia such as WPW 
syndrome and focal atrial 
tachycardia Class References
High-risk features to consider 
at EPS with or without 
catecholamine challenge are 
accessory pathways with an 
antegrade refractory period 
≤250 ms, shortest pre-excited 
RR interval during AF ≤250 ms, 
inducible atrioventricular re-
entrant tachycardia, and multiple 
accessory pathways
519,523,524
Observation without treatment 
may be reasonable in 
asymptomatic WPW patients 
who are considered to be at low 
risk following EPS, abrupt loss 
of pre-excitation during exercise 
testing, or due to intermittent 
pre-excitation on a resting ECG 
or during ambulatory monitoring
519,521
Patients with WPW may experience dramatic adverse events 
including SCD due to VF.521 The estimate for the frequency of SCD 
ranges up to 4% with more recent studies reporting a rate of 2%.519 
Alarmingly, in approximately half of the patients SCD is the first clin-
ical manifestation of the syndrome rendering appropriate risk strat-
ification essential.520
Risk assessment strategies have been recently reviewed in the 
2019 ESC Guidelines for the management of patients with supraven-
tricular tachycardia.525 Main risk factors for the development of ma-
lignant arrhythmias and SCD in patients with pre-excitation are: (a) a 
short anterograde refractory period of the accessory pathway with 
the optimal cut-off reported to be at 250 milliseconds and (b) induc-
ible atrioventricular reentrant tachycardia triggering pre-excited AF. 
A short pre-excited RR interval during AF ≤250 milliseconds and the 
presence of multiple accessory pathways have been also reported as 
risk markers. For these reasons, EPS is recommended for risk strat-
ification in subjects with asymptomatic ventricular pre-excitation 
who either have high-risk occupations or are competitive athletes. 
In patients without high-risk occupations or those who are not com-
petitive athletes, EPS should be considered for risk stratification of 
patients with asymptomatic pre-excitation that can derive a prog-
nostic benefit from prophylactic catheter ablation of the accessory 
pathway.525 Permanent Junctional Reciprocating Tachycardia (PJRT) 
re-presents a rare form of atrioventricular reciprocating tachycardia 
using a concealed accessory pathway. The incessant behaviour of 
PJRT may result in tachycardia-induced cardiomyopathy that usually 
resolves after successful treatment by RF catheter ablation.
Non-invasive testing may also be helpful. Non-invasive findings 
that identify a pathway not capable of maintaining rapid conduction 
during AF include intermittent loss of conduction over the accessory 
pathway on the resting ECG or during ambulatory monitoring, and 
abrupt loss of pre-excitation during exercise testing.523,524
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Focal atrial tachycardias are characterized by regular atrial 
activation from atrial areas with centrifugal spread and can be 
classified as sustained or non-sustained. Sustained focal atria 
tachycardia in the adult population is usually associated with a 
benign prognosis, although tachycardia-mediated cardiomyopathy 
has been reported in up to 10% of patients referred for ablation 
of incessant SVT.526 Non-sustained atrial tachycardia is frequently 
found on Holter recordings and often does not require treatment; 
however, we should consider that patients with a high premature 
atrial contractions (PAC) burden (>500/24 h) are at increased risk 
for developing of AF and be educated on the symptoms of AF.527
SUMMARY
In clinical practice and for scientific purposes, cardiologists and pri-
mary care physicians perform risk assessment in patients with car-
diac diseases or conditions with high risk of developing such.
The European Heart Rhythm Association (EHRA), Heart Rhythm 
Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the 
Latin American Heart Rhythm Society (LAHRS) set down this ex-
pert consensus statement task force to summarize the consensus 
regarding risk assessment in cardiac arrhythmias. Objectives were 
to raise awareness of using the right risk assessment tool for a given 
outcome in a given population, and to provide physicians with prac-
tical proposals that may lead to rational and evidence-based risk as-
sessment and improvement of patient care in this regard. A large 
variety of methods are used for risk assessment and choosing the 
best methods and tools hereof in a given situation is not simple. Even 
though parameters and test results found associated with increased 
risk of one outcome (e.g. death) may also be associated with higher 
risk of other adverse outcomes, specific risk assessment strategies 
should be used only for the purposes for which they are validated.
The work of this task force is summarized in a row of consensus 
statement tables.
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